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Introduction 
 
    Drug metabolizing enzymes play important roles in the pharmacokinetic disposition of 
administered drugs. When patients are given several drugs concomitantly, change in the 
pharmacokinetic disposition of those drugs by this concomitant use is represented as drug-drug 
interaction (DDI). The DDIs that affect drug metabolism are well recognized, and there are two 
types: those that inhibit drug metabolism and those that induce drug metabolizing enzymes. 
Inhibition is a particular concern because of the potential for severe adverse effects following 
the elevation of blood concentrations of drugs [1, 2]. 
    There are two types of enzyme inhibition: 1) reversible inhibition, exemplified by 
competitive inhibition, and 2) irreversible inhibition, or so-called ‘mechanism-based inhibition’ 
(MBI) [3]. In reversible inhibition, a drug inhibits an enzyme according to the relative 
concentration of the drug, whereas in MBI, a reactive metabolite binds covalently to heme iron 
or the apoprotein of an enzyme, consequently inactivating the enzyme. Mechanism-based 
inhibitors affect the blood concentration of a co-administered drug for a long time, even at an 
inhibitor concentration that cannot be detected in blood, because they continue to inhibit the 
enzyme until the inactivated enzyme is replaced by a newly synthesized one. Mechanism-based 
inhibitors require particular attention because they have been reported to cause unanticipated 
adverse effects [3, 4]. In fact, some drugs, such as sorivudine, cerivastatin, and mibefradil, have 
been withdrawn from the market because of the severe adverse effects caused by MBI-based 
DDI [2, 5]. Mechanism-based inhibitors found to have a high risk of DDIs after they have been 
launched onto the market or at a late stage of their development not only potentially injure 
patients, but can also cause pharmaceutical companies marked losses in time and resources. 
Therefore, DDIs, especially those involving MBI, are recognized as an issue that must be 
addressed in the development of new candidate drugs. 
    Guidance from the Ministry of Health, Labor and Welfare of Japan (MHLW) [6], as well as 
draft guidances from the US Food and Drug Administration (FDA) [7] and the European 
Medicines Evaluation Agency (EMEA) [8], all stipulate the need to evaluate MBI. These 
guidances recommend that DDI studies be performed as early as possible during drug 
development, and many pharmaceutical companies perform in vitro assays to evaluate the 
potential for MBI in the early discovery stage of the drug development process. In the usual 
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approaches taken to date, in vitro screening assays are performed to find compounds with lower 
MBI potential in the early discovery stage. In the later drug development stage, in vitro 
inactivation assays are used to estimate the inactivation parameters of the candidate drugs for 
MBI [9], and predictions of the clinical DDIs are made with a simple equation that calculates 
the change in the area under concentration-time curve (AUC) of the co-administered drug [10, 
11]. However, there are problems in this evaluation strategy. Because no clear criteria for 
evaluating DDI risk have been established for use in screening assays, the extent to which the 
MBI potential must be reduced cannot be determined. In the case of a drug candidate having 
some degree of MBI potential, only an easy prediction of clinical DDIs using in vitro 
inactivation parameters is unreliable to judge whether the candidate drug should be developed 
further in the late development stage. A strategy that considers the evaluation of MBI 
throughout the whole drug development process is required to prevent finding out MBI-based 
DDIs only after the drug is in clinical use and to avoid the loss of potentially effective drugs. 
    In this research, I aimed to establish an evaluation strategy for predicting MBI-based DDIs, 
applicable from the early stages through to the late stages of drug development, to effectively 
produce safe drugs with low MBI potential. To achieve this purpose, I tried to establish 
prediction methods and evaluation models that addressed the problems discussed above. First, I 
developed a simple method of rapidly predicting and visually categorizing the DDI risk of 
mechanism-based inhibitors using simple in vitro experiments and calculations. Then, I 
established an in vivo rat model to evaluate DDIs caused by mechanism-based inhibitors. Finally, 
I verified whether the in vivo DDIs observed in rats could be predicted accurately by a 
predictive model based on a physiologically-based pharmacokinetic (PBPK) model from the in 
vitro data. No study has ever demonstrated that the AUC of a probe drug is elevated by MBI in 
animals. It would be very significant if we could evaluate DDI caused by MBI using an in vivo 
animal model and if in vitro-in vivo extrapolation (IVIVE) could be validated in these animals 
before clinical studies are undertaken. This would increase our confidence in predicting clinical 
DDIs and in deciding to pursue the development of a specific drug. Using these methods and 
models, I established a strategy for the evaluation of DDIs caused by MBI, applicable from the 
early stages through to the late stages of the drug development process, in combination with the 
quantitative prediction of clinical DDIs from inactivation parameters using human enzymes. In 
this research, methodologies predominantly applicable to cytochrome P450 (CYP) 3A were 
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investigated because it is a major enzyme of oxidative metabolism in humans, and it 
metabolizes many clinically important drugs, and is reported to contribute to many serious DDIs 
[12]. 
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1. Prediction of drug-drug interactions based on time-dependent 
inhibition from high throughput screening of cytochrome P450 3A4 
inhibition 
 
1.1  Introduction 
CYPs are the main drug metabolizing enzymes expressed in human liver and are involved 
in the metabolism of many drugs on the market [12]. Drugs that inhibit CYP may elevate the 
blood concentration of co-administered drugs, resulting in DDIs, which sometimes cause severe 
adverse effects. Actually, some drugs such as terfenadine, mibefradil, astemizole, and 
cerivastatin have been withdrawn from the market due to DDI [5]. Thus, CYP 
inhibition-mediated DDI is widely recognized and the necessity of enzyme inhibition studies is 
included in the guidance from the concerned authorities [6, 7, 8]. The guidance recommends 
that DDI studies are performed as early as possible in drug development. In the case of 
compounds showing CYP inhibition in vitro, clinical DDI studies are required. CYP inhibitors 
found to have a high risk at the later stage of development can cause marked loss of time and 
resources. 
IVIVE methods to predict clinical DDI from in vitro inhibition data are well known. 
Concerning competitive inhibitors, although the ratio of inhibitor concentration to inhibition 
constant (I/Ki) is widely used for the index of DDI [13], Kato et al. recently reported that 
prediction using in vivo Ki and a PBPK model was more accurate than the conventional methods 
[14]. Concerning mechanism-based inhibitors, there have also been reports on methods to 
predict clinical DDI based on in vitro CYP inhibition data [11, 15]. These methods could predict 
increase in the AUC of a co-administrated drug accurately but are unsuitable for high 
throughput screening (HTS) technology utilized in early discovery stage of drug development 
because a substantial number of studies are required with a variety of conditions of 
preincubation time and inhibitor concentrations. To evaluate the maximum inactivation rate 
constant (kinact) and the inhibitor concentration producing half the kinact (KI,app), preliminary 
experiments are required to set the appropriate preincubation time and inhibitor concentration 
for a compound for which no information regarding its MBI potential is available. For the 
prediction of DDIs from mechanism-based inhibitors in the early stages, a simpler and speedier 
method is needed. A screening method for CYP inhibition using fluorescent substrates has been 
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reported [16, 17]. This method could be utilized to find potential MBI since mechanism-based 
inhibitors enhance the degree of inhibition according to the preincubation time, so-called 
time-dependent inhibition (TDI). This method is suitable for use with HTS because it enables a 
rapid measurement of many compounds. 
Although mechanism-based inhibitors are considered high risk for DDI, clear criteria for 
evaluating DDI risk have not been established for CYP inhibition screening. If the wrong 
criteria are used, a mechanism-based inhibitor may possibly show false negative or false 
positive predictions and results in either clinical DDI or the loss of a potentially effective drug. 
Therefore, a methodology and criteria for prediction of DDI caused by mechanism-based 
inhibitor is required to find promising compounds efficiently in early-stage screening. 
In this study, the inhibition of CYP3A4 was investigated because it metabolizes many 
drugs and has been reported to contribute to serious DDIs [12]. First, it was ascertained whether 
shift in IC50 calculated by the difference in IC50 under two conditions (with or without 
preincubation containing an inhibitor) could discriminate between competitive inhibitor and 
mechanism-based inhibitor from HTS data using a fluorescent substrate. Next, we developed a 
simple equation using the HTS data for the prediction of change in the AUC of a 
co-administered drug by MBI. We also ascertained whether we can categorize test compounds 
visually by criteria line according to the degree of AUC change predicted from that equation for 
the purpose of risk-assessment of DDI in the early stages of drug development. 
 
1.2  Materials and methods 
1.2.1  Chemicals and reagents 
    Amiodarone, amitriptyline, azithromycin, carbamazepine, diltiazem, erythromycin, 
ethynylestradiol, fluvastatin, glibenclamide, lansoprazole, methylprednisolone, mibefradil, 
mifepristone, prednisone, quinidine, terfenadine, triazolam, troleandomycin, and verapamil were 
purchased from Sigma Chemical Co. (St. Louis, MO, USA). Cimetidine, chlorpromazine, 
clarithromycin, cyclosporine, dextromethorphan, diazepam, fluoxetine, miconazole, midazolam, 
nicardipine, nifedipine, omeprazole, paclitaxel, roxithromycin, simvastatin, tamoxifen, and 
trimethoprim were obtained from Wako Pure Chemical Industries, Ltd (Osaka, Japan). 
Fluconazole and midecamycin were from ICN Biomedicals, Inc. (Aurora, OH, USA). Indinavir, 
nelfinavir, ritonavir, and saquinavir were purchased from Sequoia Research Products, Ltd 
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(Pangbourne, UK). Itraconazole, ketoconazole, and paroxetine were from LKT Laboratories, 
Inc. (St. Paul, MN, USA). Fluvoxamine was purchased from Tocris Bioscience (Bristol, UK). 
7-Benzyloxy-4-(trifluoromethyl)-coumarin (BFC) was obtained from Becton, Dickinson and 
Company (Franklin Lakes, NJ, USA). Other reagents and solvents used were of the highest or 
high performance liquid chromatography grade. 
 
1.2.2  Biological materials 
    Microsomes prepared from baculovirus-infected insect cells expressing human CYP3A4, 
cytochrome b5, and cytochrome P450 reductase, and control microsomes were obtained from 
Becton, Dickinson and Company (Franklin Lakes, NJ, USA). 
 
1.2.3  Fluorometric enzyme inhibition assay including TDI evaluation 
The evaluation of CYP3A inhibition was carried out on 96-well microtiter plates using 
MultiPROBE
TM
 IIEX Liquid Handling Robotics (PerkinElmer Japan, Yokohama, Japan). 
Fluorescence detection of the metabolite of BFC was performed using a Spectra Max Gemini 
microplate reader (Molecular Devices, Sunnyvale, CA, USA). Incubations were conducted 
based on the method provided on the Becton, Dickinson and Company website [18] as 
described below. A cofactor/serial dilution buffer containing 2.6 mmol/L -nicotinamide 
adenine dinucleotide phosphate (NADP), 6.6 mmol/L glucose-6-phosphate, 0.8 units/mL 
glucose-6-phosphate dehydrogenase, and 6.6 mmol/L magnesium chloride was prepared in 50 
mmol/L potassium phosphate (pH 7.4). The enzyme solution contained 0.35 mol/L potassium 
phosphate (pH 7.4), 10 pmol/mL CYP3A4 expressed in insect cell microsomes, 100 mol/L 
BFC, and control microsomes to give the final assay concentrations (0.04 mg of protein/mL). 
In the coincubation assay for CYP inhibition evaluation, test inhibitors were added to the 
cofactor/serial dilution buffer, giving inhibitor solutions of various concentrations. Metabolic 
reactions were started by adding the same volume of enzyme solution containing BFC to the 
above inhibitor solution. After incubation at 37°C for 30 min, the reaction was stopped by the 
addition of a stop solution (acetonitrile/0.5 mol/L Tris-base [4:1]). The same reactions without 
substrate or test inhibitor were performed as blanks for the background fluorescence and as the 
control where the reaction entirely proceeds, respectively. The metabolite of BFC, 
7-hydroxy-4-trifluoromethylcoumarin, was measured by the microplate reader using an 
9 
 
excitation wavelength of 409 nm and an emission wavelength of 530 nm. 
In the preincubation assay for TDI evaluation, test inhibitor solutions in the cofactor/serial 
dilution buffer were prepared as above and enzyme solutions without BFC were added. After 
preincubation at 37°C for 15 min, the reaction was started by adding BFC (final concentration: 
50 mol/L). After incubation at 37°C for 30 min, the reaction was stopped by the addition of the 
stop solution as described above. 
 
1.2.4  Data analysis 
Calculation of IC50 values. The equation given by Becton, Dickinson and Company was used to 
calculate IC50 values of the test inhibitors [18]. The net fluorescence intensity of each sample 
was calculated by subtracting the background fluorescence intensity of the blank sample. The 
percentage of inhibition at each concentration of inhibitor was determined by comparing the net 
fluorescence intensity in the presence of the inhibitor with that of the control sample. IC50(-) and 
IC50(+) represent the IC50 values in which the inhibitor was added to the reaction mixture 
simultaneously with BFC (coincubation assay) and before the addition of BFC (preincubation 
assay), respectively. The criteria to determine positive TDI were based on a twofold value of the 
coefficient of the variation (CV) of the IC50(-) of ketoconazole. 
 
Calculation of the inactivation constant. The ratio of v(+) to v can be described as: 
 (1-1) 
where v(+), v, Vmax(+), Vmax, S, Km, and Ki represent the metabolic rate of substrate after the 
mechanism-based inhibitor is preincubated, the metabolic rate when the inhibitor is absent, the 
maximum metabolic rate after mechanism-based inhibitor is preincubated, the maximum 
metabolic rate when the inhibitor is absent, the substrate concentration, the Michaelis constant, 
and the inhibition constant, respectively. Assuming that the concentration of the inhibitor does 
not change during the preincubation, the following equations can be described [3]: 
       (1-2) 
     (1-3) 
Vmax(+) × S
Km× 1 + 
IC50(+)
Ki
+ S
Vmax × S
Km + S
v(+)
v
=
kobs = 
kinact × Iu
KI,app + Iu
Vmax(+) = Vmax × exp
(- kobs × t)
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where kobs, Iu and t represent the apparent inactivation rate constant, unbound concentration of 
inhibitor and preincubation time in the assay, respectively. When the metabolic response is 
inhibited by MBI to 50%, eq. (1-1) gives v(+)/v = 0.5 and Iu can be assumed equal to IC50(+). 
When the substrate concentration is efficiently smaller than Km, kinact can be described as follows 
using eqs. (1-1) - (1-3): 
  (1-4) 
Because Ki is postulated to be equal to KI,app (see Estimation of inactivation constant: 
certification of equivalence of Ki and KI,app below for a detailed explanation), the following 
equation can be described when the substrate concentration is smaller than the Km value: 
      (1-5) 
Thus, kinact may be calculated using IC50(+) and IC50(-) as follows: 
 
 
 
(1-6) 
 
Calculation of AUC change. The remainder of the active enzyme when an inhibitor is present is 
expressed by the following equation [3]: 
  (1-7) 
where E, E0, and kdeg represent the active metabolic enzyme in the liver, total concentration of 
metabolic enzyme, and the degradation rate constant (turnover rate constant) of metabolic 
enzyme, respectively. At steady state, the following equation can be derived from eq. (1-7): 
1 +
Ki
IC50(+)
2
ln
1 + 
KI,app
IC50(+)
t
kinact = 
Ki = KI,app = IC50(-)
dE
dt
- (kinact × E × Iu)
KI,app + Iu
+ kdeg × E0 – kdeg × E=
1 +
IC50(+)
2
ln
1 + 
IC50(-)
IC50(+)
t
kinact = 
IC50(-)
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   (1-8) 
Assuming the elimination of a substrate from the blood entirely to depend on the metabolism of 
a single pathway, the ratio of E0 to E is equal to the rate of change in the AUC of a substrate 
when a mechanism-based inhibitor is orally administered in combination with the substrate. 
Assuming the clearance of a substrate to be proportional to the average enzyme activity at 
steady state, Eav, leads to the equation: 
 (1-9) 
where the ratio of AUC(+)/AUC(-) represents the rate in change of the AUC of a substrate when 
a mechanism-based inhibitor is administered in combination with a substrate. When eq. (1-6) is 
substituted into eq. (1-9), the ratio of AUC change of a substrate is determined as follows: 
           
          
   
 
(1-10) 
 
Prediction of DDI. Prediction of the ratio of AUC change was calculated using eq. (1-10). Data 
of drugs reported to be inhibitors of CYP3A4 [13] or shown to cause DDI attributed to CYP3A4 
were used to verify the prediction method. The pharmacokinetic parameters of these drugs in 
healthy volunteers or patients with or without co-administrations of other drugs were referred to 
reports (Table 1-1). We used 0.000164 min
-1
 for kdeg, the published value which showed a 
decrease rate of 6β-hydroxycortisol/cortisol ratio after stopping repeated administration of 
rifampin in humans [19]. For the value of Iu, we used the average unbound concentration of an 
inhibitor in blood at the steady state (Css,u) calculated by dividing the AUC of unbound 
concentration by the dosage interval (). The values for Css,u/IC50(-) and IC50(-)/IC50(+) of the 
1 + 1 + 
kinact
kdeg
× Iu KI,app
Iu
KI,app
1 + 
= 
E
E0
AUC(+)
AUC(-)
= 
1 + 1 + 
kinact
kdeg
Iu
KI,app
× Iu KI,app
1 + 
E0
Eav
= 
1 +
IC50(+)
2
ln
1 + 
IC50(+)
kdeg × t
1 +1 + ×
Iu
IC50(-)
1 + 
Iu
IC50(-)
AUC(+)
AUC(-)
= 
IC50(-)
IC50(-)
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CYP3A4 inhibitors were calculated and plotted; the relationships between the plotted results 
and predicted criteria curves for 200% and 110% of change in AUC were evaluated. 
 
Table 1-1  Published data of DDIs used for prediction and verification 
 
 
Estimation of inactivation constants: certification of equivalence of Ki and KI,app. The kinetic 
model for MBI is shown in Figure 1-1. The amount remaining of each enzyme was calculated as 
follows: 
        (1-11) 
Furthermore, each relationship can be expressed as: 
        (1-12) 
         
(1-13) 
         
(1-14) 
         
(1-15) 
  
(1-16) 
         
Drug I u 
20) fu 
20) Css,u/IC50(-) Interacted drug Change in AUC Reference
(μg/mL) (%)
Amiodarone 0.000192 0.0002 0.0000347 Carbamazepine no change Leite et al. 
24)
Azithromycin 0.102 0.5 0.000453 Midazolam 127 Zimmermann et al. 
25)
Cimetidine 0.976 0.81 0.0930 Triazolam 132 Friedman et al. 
26)
Clarithromycin 0.404 0.54 0.0189 Midazolam 961 Gorski et al. 
27)
Diazepam 0.00792 0.013 0.000336 Methadone no change Pond et al. 
28)
Diltiazem 0.0144 0.22 0.00137 Triazolam 338 Varhe et al. 
29)
Erythromycin 0.0611 0.16 0.00386 Felodipine 249 Bailey et al. 
30)
Fluconazole 5.89 0.89 0.544 Cyclosporine 187 Sud et al. 
31)
Fluoxetine 0.00372 0.06 0.00138 Alprazolam 133 Lasher et al. 
32)
Fluvastatin 0.0000355 0.01 0.00000235 Cyclosporine no change Scripture and Pieper 
33)
Fluvoxamine 0.0113 0.23 0.000795 Midazolam 139 Lam et al. 
34)
Indinavir 0.111 0.39 0.575 Sildenafil 440 Merry et al. 
35)
Itraconazole 0.0000949 0.002 0.000716 Simvastatin 1861 Neuvonen et al. 
36)
Ketoconazole 0.0266  
21)
0.01 1.03 Triazolam 819 Boxenbaum 
21)
Mibefradil 0.000953  
22)
0.004  
22)
0.0224 Midazolam 886 Veronese et al. 
37)
Ritonavir 0.0785  
23)
0.015 5.59 Alprazolam 248 Greenblatt et al. 
38)
Verapamil 0.00349 0.1 0.000913 Midazolam 292 Backman et al. 
39)
E0 = E + ES + EI + Einact
dS
dt
= - k1 × E × S + k2 × ES
dES
dt
= k1 × E × S - k2 × ES - k3 × ES
dPs
dt
= k3 × ES
dI
dt
= - k4 × E × I + k5 × EI
dEI
dt
= k4 × E × I - k5 × EI - k6 × EI - k7 × EI
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(1-17)  
  
 (1-18) 
Assuming a steady state, the reaction is expressed by: 
         
(1-19) 
 
When an inhibitor is present, we can ignore Einact in the initial reaction and eq. (1-19) can be 
expressed as follows: 
         
(1-20) 
The following equations thus may be expressed under steady state conditions. 
         
(1-21) 
 
         
(1-22) 
         
(1-23) 
 
When Km is significantly greater than S, eq. (1-23) can be rewritten as: 
         
(1-24) 
Eq. (1-24) shows that KI,app is approximately equal to Ki [3] and, in the case of Km greater than S, 
Ki is equal to IC50(-). 
Therefore, the equation below may be approximately expressed when evaluating the initial 
inactivation rate under steady state conditions. 
     (1-25) 
 
Ki = KI,app = IC50(-)
Ki = 
k5 + k6 + k7
k4
dEinact
dt
= k7 × EI
dPi
dt
= k6 × EI
dPs
dt
= k3 × ES = 
k2 + k3
k1
+ S
k3 × E0 × S
=
Km + S
Emax × S
dPs
dt
k3 × E0 × S
=
Km × 1 +
I
Ki
+ S
dPi
dt
k6 × E0 × I
=
Ki × 1 +
S
Km
+ I
dEinact
dt
k7 × E0 × I
=
Ki × 1 +
S
Km
+ I
dEinact
dt
k7 × E0 × I=
Ki + I
14 
 
 
Figure 1-1  Enzyme inhibition kinetic models by a mechanism-based inhibitor 
E, enzyme; S, substrate; Ps, metabolite of substrate; I, inhibitor; and Pi, metabolite of inhibitor. 
 
1.3  Results 
1.3.1  TDI evaluation 
IC50 for CYP3A4 inhibition under conditions of both pre- and coincubation were estimated. 
The relationship between inhibitor concentration and percentage of inhibition of metabolism of 
BFC for the model drugs is shown in Figure 1-2, and the calculated values for IC50(-)/IC50(+) 
are shown in Figure 1-3. The assay precision (coefficient of variation) for each experiment (n = 
3) was less than 25%. All calculated values for IC50 ratios were greater than 1 with the exception 
of ketoconazole for which no MBI has been reported. 
Using this method, IC50 and IC50 ratios of CYP3A4 inhibition for the CYP3A4 inhibitors 
were estimated (Table 1-2). Among 46 drugs containing the model drugs evaluated, 41 showed 
IC50(-) under 100 mol/L. Twenty six drugs were judged TDI-positive using the criteria of 
having an IC50 ratio of more than 1.3 determined from CV for TDI-negative ketoconazole. 
 
 
 
E + S ES E + Ps
k1
k2
k3
E + I
k4
k5
EI
Einact
k7
k6
E + Pi
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Figure 1-2  Inhibition profiles for BFC metabolism at various concentrations of inhibitors 
in recombinant CYP3A4 
Values represent the average of three experiments. Inhibition percentages for coincubation 
(closed circles) and 15-min preincubation (open circles) are shown. 
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Figure 1-3  Effects of preincubation on inhibitory potential against recombinant CYP3A4 
activity 
Bars represent the ratio of IC50 values from the coincubation assays to the 15-min preincubation 
assays for the drugs listed. Data are the mean ± standard deviation (n=3). 
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Table 1-2  IC50 of CYP3A4 inhibitors for inhibition of CYP3A4 activity and effects of 
preincubation on IC50 
 
Values are the average of two experiments.  
Test compound
IC50(-)
μmol/L
IC50 (+)
μmol/L
IC50(-)/IC50(+)
Ratio
Amiodarone 8.58 1.02 8.39
Amitriptyline 59.21 125.01 0.47
Azithromycin 300.48 68.55 4.38
Carbamazepine 219.44 246.97 0.89
Chlorpromazine 30.37 28.54 1.06
Cimetidine 41.57 34.01 1.22
Clarithromycin 28.55 11.08 2.58
Cyclosporine 3.73 7.53 0.49
Dextromethorphan 93.02 58.15 1.60
Diazepam 82.84 17.63 4.70
Diltiazem 25.33 3.14 8.08
Erythromycin 21.58 7.86 2.75
Ethynylestradiol 2.10 1.04 2.03
Fluconazole 35.32 60.68 0.58
Fluoxetine 8.73 6.30 1.38
Fluvastatin 36.68 8.74 4.20
Fluvoxamine 44.65 16.13 2.77
Glibenclamide 12.04 5.62 2.14
Indinavir 0.31 0.61 0.52
Itraconazole 0.19 0.27 0.70
Ketoconazole 0.05 0.12 0.40
Lansoprazole 36.88 55.98 0.66
Methylprednisolone 35.00 47.90 0.73
Mibefradil 0.09 0.04 2.34
Miconazole 0.29 0.34 0.85
Midazolam 2.29 0.77 2.98
Midecamycin 55.14 28.16 1.96
Mifepristone 0.81 0.23 3.47
Nelfinavir 0.38 0.39 0.97
Nicardipine 0.32 0.25 1.29
Nifedipine 7.61 5.97 1.28
Omeprazole 89.92 43.07 2.09
Paclitaxel 38.38 18.74 2.05
Paroxetine 3.24 2.00 1.62
Prednisone 33.31 51.72 0.64
Quinidine 97.00 71.78 1.35
Ritonavir 0.05 0.05 0.93
Roxithromycin 115.89 26.57 4.36
Saquinavir 16.26 12.35 1.32
Simvastatin 6.14 2.18 2.81
Tamoxifen 13.26 14.97 0.89
Terfenadine 2.40 2.64 0.91
Triazolam 145.17 49.55 2.93
Trimethoprim 243.13 232.75 1.04
Troleandomycin 1.07 0.36 2.97
Verapamil 8.41 0.85 9.86
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1.3.2  Prediction of AUC change 
A comparison of the ratios for the AUC change of substrates co-administered with a 
mechanism-based inhibitor predicted using eq. (1-10) and the reported ratios in clinic is shown 
in Figure 1-4. The results show good correlation (r = 0.997) for 11 of the drugs we predicted to 
be TDI-positive compounds. 
The relationship between IC50 and the ratios of AUC change is shown in Figure 1-5. The 
ratios for AUC change obtained from published clinical DDI data (Table 1-1) were classified 
into three risk groups: low (less than 110%), medium (110% to 200%), and high (more than 
200%). The data superimposed on the predicted criteria curves show that most 
mechanism-based inhibitors which elevated the AUC of a co-administered drug more than 
200%, with the exception of ritonavir, fell in the area above the predicted curve of 200% (high 
risk) of AUC change. Mechanism-based inhibitors which elevated AUC more than 110% fell in 
the area above the predicted curve of 110% (medium risk) of AUC change. Drugs reported to 
not elevate the AUC of a co-administered drug did not fall in the high risk area of the graph. 
 
 
Figure 1-4  Relationship between the predicted ratios of AUC change of co-administrated 
drugs and the ratios reported in clinic from mechanism-based inhibitors 
Prediction of the change in AUC was calculated using equation 1-10. The line represents the 1:1 
correlation. 
 
0
2
4
6
8
10
12
0 2 4 6 8 10 12
O
b
se
rv
ed
 c
h
an
g
e 
in
 A
U
C
Predicted change in AUC
19 
 
 
Figure 1-5  Quantitative categorization of the predictions of DDI involving CYP 
inhibition 
A scatter diagram of the relationship between the IC50 ratio and Css,u/IC50(-) calculated using our 
method. The dotted and bold line show the calculated relationship between the IC50 ratio and 
Css,u/IC50(-) when the rate of change in AUC is 110% and 200%, respectively. Plots represent 
inhibitors reported to change in the AUC of co-administered drugs of more than 200% (closed 
triangles), 110%-200% (closed rhombuses), less than 110% (open squares), and no interaction 
reported (open circles). 
 
1.4  Discussion 
In the evaluation of CYP3A4 inhibition with a fluorescent substrate, differences between 
the values for IC50(+) and IC50(-), obtained under pre- and coincubation, respectively, were 
investigated. Utilization of the shift in IC50 between the two conditions was verified to be valid 
for prediction of mechanism-based inhibitors. The results from 5 compounds known to cause 
MBI (erythromycin, diltiazem, fluoxetine, troleandomycin, and verapamil) [15, 40-42] showed 
each compound to have a ratio of IC50(-) to IC50(+) greater than 1. The IC50 ratio for 
ketoconazole, known to not cause MBI [43], was smaller than 1 (Figure 1-3). Therefore, the 
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IC50 ratio would be an indication of whether or not the test compound causes MBI. Because 
twofold CV value of IC50(-) of ketoconazole was calculated to be under 0.3 (n = 3, CV = 13.6%), 
we concluded that a test compound with an IC50 ratio greater than 1.3 is TDI-positive. 
From the evaluation of the IC50 ratios for 46 CYP3A4 inhibitors, 26 of the compounds 
showed an IC50 ratio of more than 1.3 (Table 1-2), indicating that many drugs on the market are 
TDI-positive. However, some drugs such as ritonavir, reported to be a mechanism-based 
inhibitor [44], were judged to be TDI-negative. Figure 1-6 shows the relationship between 
various concentrations of inhibitors and percentage of inhibition from a coincubation assay in 
which competitive inhibition is postulated to occur. In the case of ritonavir, the experimental 
values were different from the theoretical curve calculated for competitive inhibition. The 
experimental values coincided with the theoretical curve in the case of ketoconazole (Figure 
1-6), correctly judged as MBI-negative. The discrepancy in the ritonavir case may be due to a 
large kinact [45]. Compounds which have a large kinact can cause MBI within a short period 
(several minutes), and so the detection of IC50 shifts of these compounds after preincubation 
would be difficult because TDI results even in the incubation period for the reaction of substrate 
drugs (30 minutes in the present study). In fact, Perloff et al. reported that the length of 
preincubation time did not affect the degree of IC50 shift when azamulin, whose kinact is large 
(1.2 min
-1
), was used as an inhibitor [46]. For such compounds, the reaction time of the 
substrate in this study may be too long, resulting in a false-negative judgment for TDI. The gap 
between experimental values and the theoretical curve may indicate a mechanism other than 
competitive inhibition and, if a difference is found, we may have to consider that the MBI 
potential of such a test compound has been overlooked. Another point that needs attention is 
that not all compounds showing TDI by this evaluation are mechanism-based inhibitors. For 
example, a compound that converts to a metabolite causing stronger reversible inhibition will be 
judged TDI-positive. This IC50 shift method which does not include dilution of the reaction 
solution after preincubation tends to be influenced by metabolites showing reversible inhibition. 
To avoid overlooking a promising lead compound, this possibility must be considered. Even 
considering the weak points mentioned above and the necessity of evaluation of kinact and KI,app 
to predict DDI by MBI in the late development stage, this method may be sufficiently useful for 
screening many compounds in the early discovery stage. 
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Figure 1-6  Comparison of experimental residual activity with theoretical residual 
activity in the coincubation assay 
Theoretical curves are shown with experimental data (closed circles). Residual activity is shown 
as the percentage of the activity of the control sample. 
 
Methods to predict clinical DDI from mechanism-based inhibitors based on in vitro CYP 
inhibition data have been reported [11, 15]. However, because the methods require measurement 
of many samples obtained under a variety of incubation conditions, they are unsuitable for HTS. 
We have established an easy prediction method optimal for the screening utilized in the early 
stages to evaluate DDI risk caused by MBI. Because the IC50 ratio used in the determination of 
the TDI indicates change in the degree of inhibition during preincubation, this value is closely 
related to kinact. If the metabolic rate of a substrate is evaluated using the initial velocity as 
described in 1.2.4 Estimation of inactivation constants: certification of equivalence of Ki and 
KI,app, an approximate value of KI,app can be calculated using the IC50. Therefore, using the 
approximate values of kinact and KI,app calculated from the IC50 values and the kdeg calculated from 
the reported data, we can predict the ratio of AUC change of a co-administrated drug using the 
equation we derived (eq. 1-10). Figure 1-4 shows that the ratios of AUC change predicted using 
our method were close to those observed in clinics. Many false negatives result from the 
prediction method for competitive inhibitors using the ratio of Cmax,u/Ki, where Cmax,u represents 
the unbound maximum concentration in blood (data not shown). However, with our method 
using Css,u as the inhibitor concentration, there were no false negative predictions, suggesting 
that our method more precisely predicts DDI caused by a mechanism-based inhibitor. 
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In this study, many drugs were judged to be TDI positive, but some of those drugs can be 
used without causing profound DDI problems and thus may be developed as safe drugs. To 
determine whether or not to develop a compound showing some degree of TDI, we tried to 
devise a method to categorize compounds visually into the degree of DDI risk according to IC50 
obtained during early-stage evaluation. Although it is necessary to calculate the KI,app and kinact to 
predict DDI caused by MBI in the conventional methods, our method requires no 
experimentation other than CYP inhibition screening for the evaluation of TDI. To classify risk, 
we used the ratio of change in the AUC of co-administered drug (110% or 200%) as determined 
by the relationship between the IC50(-)/IC50(+) ratio and the value of Css,u/IC50(-) (Figure 1-5). 
This classification is commonly used as a criterion for risk of DDI [47]. From our estimations, 
we found that the greater the IC50 ratio, the lower the Css,u/IC50(-) needed to be to elevate the 
AUC. Thus, a compound for which the degree of change in the inhibition between pre- and 
coincubation is great must have a much lower level of blood concentration than the IC50(-) value 
to not induce DDI. According to our prediction, in the case of an IC50 ratio of 2, a difference of 
less than 300-fold between Css,u and IC50(-) is necessary to avoid a high risk of DDI. To satisfy 
this condition, considerably more pharmacological activity than CYP3A4 inhibition activity is 
required. 
When plotting the data from our evaluation of CYP3A4 inhibitors, we noticed that the 
degree of AUC change by inhibitors observed in clinics was substantially consistent with the 
DDI risk criteria of 200% and 110% (Figure 1-5). A few cases of inhibition assays using 
fluorescent substrates and recombinant enzymes have reported lower IC50 values with 
coincubation [48] and an inhibition assay using a recombinant enzyme showed an 
overestimation of MBI potential compared with assays using human liver microsomes [49]. 
However, even if overestimation occurs, using a fluorescent substrate is effective for screening 
compounds that cause DDI, because false negatives do not tend to occur. Importantly, false 
negatives were not observed in our evaluations, with the one exception of ritonavir (Figures 1-4 
and -5).With our method, most mechanism-based inhibitors that caused AUC changes of more 
than 200% in clinics fell into the high risk area, not the low risk area. Obvious false positive 
predictions were not observed. Drugs reported not to cause DDIs were not found in the high risk 
area. Although many compounds with no reported DDI were plotted, this appears to mean that 
they do not cause severe DDI. Therefore, we conclude that a simple assessment of the risk of 
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DDI from mechanism-based inhibitors could be possible using this method in the early 
discovery stages. As shown by eq. (1-10), Iu is an important factor for predicting DDI. In this 
study, amiodarone, diazepam, and fluvastatin each showed an IC50 ratio more than 4 (Table 1-2), 
although they have not been reported to cause clinical DDI (Table 1-1). Although clarithromycin 
and erythromycin showed smaller IC50 ratios, they have been reported to cause DDI. Prediction 
of DDI by a mechanism-based inhibitor may be possible by both TDI evaluation in vitro and the 
Iu from clinical data. Another method for screening many compounds in the early stages that 
utilizes the IC50 shift to distinguish between mechanism-based inhibitors and competitive 
inhibitors has been reported [50]. However, the strategy requires additional experiments to 
analyze the DDI risk of TDI-positive compounds in detail. Our method presented here appears 
to have the advantage of simplicity by expanding the IC50 shift to the categorization of the DDI 
risk of compounds which can be adapted to screening in the early discovery stage. In the case of 
a drug candidate with potential MBI, more rigorous evaluation using prediction methods from 
the kinact and KI,app in a PBPK model [15] will be needed to promote development of that 
candidate. Additionally, there is the possibility that prediction from in vitro data might lead to 
incorrect prediction attributed to the use of uncertain and biased parameters (i.e. the turnover 
rate of the enzyme and inhibitor concentration where the inhibitor is uptaken by a transporter or 
highly binds to a serum protein). Therefore, implementation of assessment using in vivo 
evaluation may improve the predictability and consequently lead to more reliable 
decision-making. 
In conclusion, we established a simple method for rapidly predicting and categorizing the 
DDI risk of mechanism-based inhibitors of CYP3A4 using simple experiments and calculations. 
Comprehension of the DDI potential as early as possible enables safe compounds with weak 
inhibition to be developed. This method takes advantage of early-stage screening technology 
and should contribute to producing safe drugs with low risk of DDI. 
 
 
 
  
24 
 
2. In vivo approach for the evaluation of mechanism-based inhibition 
of cytochrome P450 3A in rats 
 
2.1  Introduction 
    Inhibition of drug metabolizing enzymes, especially MBI, is recognized as an 
indispensable issue in the development of new drug entities because mechanism-based 
inhibitors have been reported to cause unanticipated adverse effects arising from DDIs [3, 4], 
and some such dangerous drugs have been withdrawn [5]. In vitro DDI evaluations are 
performed in many drug industries using readily available high-throughput screening systems, 
and evaluation of TDI using these screening systems has been previously reported [16, 17]. 
Although clear criteria for evaluating DDI risk have not been established for CYP inhibition 
screening, we established a simple method for rapidly predicting and visually categorizing the 
DDI risk of mechanism-based inhibitors of CYP3A4 using CYP inhibition screening data in the 
early discovery stage as described in Chapter 1. However, more detailed evaluation and 
prediction are needed in stages when some candidate drugs are selected. In vivo evaluation can 
assess the responses of the whole body, which involve phenomena that are difficult to anticipate 
from in vitro studies. It would enhance the understanding of chemists and pharmacologists. In 
vivo animal model for DDIs, and in combination with in vitro inhibition assays using human 
enzymes, could allow more efficient decision-making in the drug development process. 
    A few reports showing that the AUC of the probe is elevated by co-administration of a 
mechanism-based inhibitor in animals in vivo have been published, but that the DDI was caused 
mainly due to MBI remains unclear [51, 52]. We speculated that the small number of reports on 
the application of an in vivo approach to the evaluation of MBI in animals was attributed to 
interspecies difference in drug metabolism, as exemplified by the metabolic enzyme CYP3A4 in 
human liver [53, 54] and CYP2C11 in male rat liver [55]. It is known that simvastatin is mainly 
metabolized by CYP3A4 in human and by CYP2C11 in male rat [56, 57] and thus the 
possibility remains that the CYP3A inhibitor gives rise to DDI in human, but not in rat. Another 
example is the study of erythromycin in which repeated administration to rats brought about 
both the formation of a metabolic intermediate complex and the induction of CYP, and 
consequently there was no overall change in the enzyme activity level [58]. It is well known that 
erythromycin causes DDI in humans [15] but, as with the case of erythromycin and others, 
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evaluation of the risk of MBI-induced DDI in humans is not reproducible in animals [59]. 
Analysis of MBI-induced DDI in animals in vivo appears to be difficult and thus has not been 
investigated. However, if it is possible to establish an in vivo animal model for evaluating DDI 
caused by MBI, it would make an impact on judgment of drug development and be worth trying 
to establish. The demonstration of MBI in animals in vivo, and in combination with in vitro 
inhibition assays using human enzymes, could lead to more efficient decision-making toward 
clinical studies. Highly accurate evaluation before clinical stages would save time and the high 
cost of late-stage clinical development and, more importantly, might help reduce the risk of 
severe DDIs in humans. Moreover, the results of in vitro and in vivo DDI studies in animals 
could be exploited to improve the design of clinical DDI studies. 
The purpose of this study was to ascertain whether a mechanism-based inhibitor known to 
induce MBI with CYP3A in humans causes MBI in animals. Rats were selected because of the 
vast accumulation of information concerning their physiological parameters and their wide use 
in absorption, distribution, metabolism, and excretion (ADME) studies from early to late stage 
development. CYP3A4 is a major enzyme for oxidative metabolism in humans and metabolizes 
many clinically important drugs [12]. The inhibitory potential for CYP3A4 in a drug appears to 
indicate a high risk of severe DDIs. Midazolam (MDZ) is metabolized predominantly by 
CYP3A4 in human liver [60, 61] and is available for in vivo probes, so it is used generally as the 
substrate of human CYP3A4 [7]. Therefore, we used MDZ as the substrate for the evaluation of 
DDI in rats. 
In the present study of demonstrating DDI induced by MBI in rats, an in vivo investigation 
was performed. Before the in vivo assessment, the contribution of CYP3A to the metabolism of 
MDZ in male rat liver was examined. Seven inhibitors known to cause MBI in humans were 
evaluated for their inhibitory potential against the metabolism of MDZ in rat liver microsomes 
(RLM). Mibefradil, the inhibitor which exhibited the most extensive inhibition in vitro, was 
then assessed for its influence on the pharmacokinetics of MDZ in vivo in rats. The results 
confirmed that the DDI caused by MBI in humans is reproducible in rats. 
 
2.2  Materials and methods 
2.2.1  Chemicals and reagents 
    MDZ, clarithromycin, verapamil hydrochloride, and polyethylene glycol 400 (PEG400) 
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were purchased from Wako Pure Chemical Industries, Ltd (Osaka, Japan). Diltiazem 
hydrochloride, erythromycin, 17-ethynylestradiol, mibefradil dihydrochloride, mifepristone, 
and the reduced form -nicotinamide adenine dinucleotide phosphate (NADPH) were obtained 
from Sigma Chemical Co. (St. Louis, MO, USA). 4-Hydroxymidazolam, 1’-hydroxymidazolam, 
and bufuralol hydrochloride were purchased from Ultrafine Chemicals Ltd (Manchester, UK). 
Other reagents and solvents used were of the highest or high performance liquid 
chromatography grade. 
 
2.2.2  Biological materials 
    Pooled male rat liver microsomes (RLM) were purchased from Xenotech LLC (Lenexa, KS, 
USA). Microsomes prepared from baculovirus-infected insect cells expressing rat CYP3A2, 
cytochrome b5, and cytochrome P450 reductase (rrCYP3A2), and control microsomes were 
obtained from Becton, Dickinson and Company (Franklin Lakes, NJ, USA). Polyclonal anti-rat 
CYP1A2, anti-rat CYP2C11, anti-human CYP2D6, and anti-rat CYP3A2 antibodies were 
purchased from Daiichi Pure Chemicals Co., Ltd (Tokyo, Japan). According to the data from 
the manufacturer, the CYP1A2, 2D6, and 3A2 antibodies inhibit specifically the reaction of 
CYP1A2 (and 1A1), 2D6, and CYP3A2, respectively. The CYP2C11 antibodies inhibit the 
reaction of CYP2C11 extensively, showing inhibition of CYP2B1 and 2B2 to a slight degree. 
Control goat and rabbit sera were obtained from Invitrogen Corp. (Carlsbad, CA, USA). 
 
2.2.3  Animals 
    Male Sprague-Dawley rats at 8 weeks of age (weighing 261–301 g) were purchased from 
Japan SLC, Inc. (Hamamatsu, Japan). The animals were maintained on a 12 h/12 h, light/dark 
cycle with free access to CE-2 diet (CLEA Japan Inc., Tokyo, Japan) and water. The protocols 
for the animal experiments were approved by our institutional committee for animal care and 
use. 
 
2.2.4  Immuno-inhibition of MDZ metabolism 
    Immuno-inhibition was performed by preincubating microsomal protein with polyclonal 
anti-sera (12 L/45 g protein for RLM and /2.4 pmol for rrCYP3A2) or control goat or rabbit 
sera for 30 min at room temperature. After dilution in 0.1 mol/L potassium phosphate buffer (pH 
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7.4) (final protein and enzyme concentrations of 0.15 mg/mL and 8 pmol/mL, respectively), 
MDZ was added to achieve a final concentration of 200 nmol/L, followed by preincubation for 
5 min at 37°C. The reaction was started by the addition of NADPH and incubated at 37°C. At 
times 0 and 10 min, the reaction was stopped by adding to acetonitrile containing 1 pmol of 
bufuralol as the internal standard (IS). Experiments were conducted in triplicate. 
 
2.2.5  Inhibition of MDZ metabolism by CYP3A inhibitors 
The evaluation of CYP3A inhibition was carried out on 96-well microtiter plates using 
MultiPROBE
TM
 IIEX Liquid Handling Robotics (PerkinElmer Japan, Yokohama, Japan). In the 
coincubation assay, test inhibitors were added to 0.1 mol/L potassium phosphate buffer (pH 7.4) 
containing NADPH (final concentration: 1 mmol/L), giving inhibitor solutions of various 
concentrations. Metabolic reactions were started by the addition of RLM (final concentration: 
0.04 mg of protein/mL) containing MDZ (final concentration: 200 nmol/L) to the above 
inhibitor solution. After incubation at 37°C for 15 min, the reaction was stopped by the addition 
of acetonitrile containing 1.5 pmol of bufuralol as the IS. Experiments were conducted in 
duplicate. 
In the preincubation assay for the evaluation of TDI, inhibitor solutions in 0.1 mo/L 
potassium phosphate buffer (pH 7.4) containing NADPH were prepared as above and RLM 
without substrate were added. After preincubation at 37°C for 30 min, the reaction was started 
by the addition of MDZ. After incubation at 37°C for 15 min, the reaction was stopped by the 
addition of acetonitrile containing 1.5 pmol of bufuralol as the IS. Experiments were conducted 
in duplicate. 
 
2.2.6  In vivo study 
    MDZ was dissolved at 10 mg/mL in ethanol/PEG400/water (1:1:2). Mibefradil 
dihydrochloride was dissolved in water to obtain concentrations of 6 or 12 mg/mL mibefradil. 
Both MDZ and mibefradil were administered orally at 1 mL/kg
 
to rats under a fed condition. 
Three regimens (5 or 6 animals per group) were studied: 1) MDZ administered 24 hour after 
pretreatment of 6 mg/kg mibefradil, 2) MDZ administered 24 hour after pretreatment of 12 
mg/kg mibefradil, and 3) MDZ administered with 6 mg/kg mibefradil simultaneously. Control 
animals were administered distilled water instead of mibefradil. Blood samples were collected 
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from the jugular vein at 0.17, 0.5, 1, 1.5, 2, and 3 hour after administration of MDZ and 
immediately centrifuged to obtain plasma samples. The plasma samples were kept at 
approximately –80°C until analysis. 
 
2.2.7  Analysis of MDZ and mibefradil 
    The concentrations of MDZ, 1’-hydroxymidazolam, 4-hydroxymidazolam, and mibefradil 
were measured by high-performance liquid chromatography-electrospray tandem mass 
spectrometry. 
    Samples for the in vitro study were prepared with Oasis HLB Elution plates (Waters 
Corp., Milford, MA, USA). After loading samples and washing with methanol-water (5:95), 
analytes were eluted with 60 L methanol and then 90 L of 10 mmol/L ammonium acetate was 
added. An adequate volume of this solution was injected to a QuattroII tandem mass 
spectrometer (Micromass Ltd, Manchester, UK) equipped with a MAGIC2002 liquid 
chromatograph (Michrom BioResources, Inc., Auburn, CA, USA) and a HTC PAL autoinjector 
(CTC Analytics AG, Zwingen, Switzerland). The chromatography was performed on a 
Symmetry C18 column (150 × 2.1 mm i.d., Waters Corp.) with 0.1% formic acid-methanol 
(59:41) as the mobile phase at a flow rate of 200 L/min. The electrospray ionization was 
operated in the positive ion mode, and quantification was obtained using a selected 
reaction-monitoring method (MDZ: m/z 326 > 291, 1’-hydroxymidazolam: m/z 342 > 203, 
4-hydroxymidazolam: m/z 342 > 297, IS (bufuralol): m/z 262 > 188). 
    Plasma samples with added IS were prepared with Oasis MCX Elution plates (Waters 
Corp.). After loading samples and washing stepwise with 2% formic acid and methanol, 
analytes were eluted with 40 L of methanol containing 2% ammonium and then 40 L water 
was added. From this solution, 10-L portions were injected into a Quattro micro tandem mass 
spectrometer (Micromass Ltd) equipped with an Alliance 2795 Separation Module (Waters 
Corp.). The chromatography was performed on a SunFire C18 column (30 × 2.1 mm i.d., Waters 
Corp.) at a flow rate of 200 L/min. The mobile phases were A (0.1% formic acid aqueous, v/v) 
and B (methanol containing 0.1% formic acid, v/v). The following gradient program was used: 
0 to 3.5 min, linear change from mobile phase A/B (95:5, v/v) to A/B (5:95, v/v); 3.5 to 4 min, 
maintenance of A/B (5:95, v/v); and 4.1 to 9 min, maintenance of A/B (95:5, v/v). The 
electrospray ionization was operated in the positive ion mode, and quantification was obtained 
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by selected reaction-monitoring (mibefradil: m/z 496 > 202, MDZ and IS (bufuralol): same as 
above). 
 
2.2.8  Data analysis 
Inhibitory effects of anti-sera on metabolism of MDZ. The elimination constant was calculated 
from the slope of the semilogarithmic plot of the residual concentration of MDZ. The 
percentage inhibition for each anti-CYP anti-serum was calculated by comparing the elimination 
constant in the presence of anti-serum with the control serum. 
 
Inhibition of MDZ metabolism by CYP3A inhibitors. The intrinsic clearance (CLint) was 
calculated by dividing the metabolite concentration after a 15-min reaction by the AUC of MDZ 
in the reaction buffer. The AUC was calculated using the logarithmic trapezoidal method. The 
concentration of MDZ in a blank sample without NADPH represented the initial concentration. 
The percentage inhibition at each concentration of inhibitor was calculated by comparing the 
CLint in the presence of the inhibitor with that of the control sample. IC50(-) and IC50(+) 
represent the IC50 values in which the inhibitor was added to the reaction mixture 
simultaneously with MDZ (coincubation assay) and before the addition of MDZ (preincubation 
assay), respectively. 
 
Calculation of pharmacokinetic parameters. Pharmacokinetic parameters were estimated using 
WinNonlin (Pharsight, Mountain View, CA, USA) by non-compartment analysis. AUCs were 
calculated by the linear-logarithmic trapezoidal method where the logarithm of plasma 
concentration was applied after the time to reach maximum plasma concentration (Tmax). 
 
2.2.9  Statistical analysis 
    A comparison of the maximum plasma concentration (Cmax) and AUC values of MDZ in 
the control group with values from the co-administration with mibefradil group was performed 
using an SAS system (SAS Institute, Inc., Cary, NC, USA). Data transformed into logarithms 
were analyzed using Dunnett’s multiple comparison test. 
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2.3  Results 
2.3.1  CYP3A specificity of MDZ metabolism in RLM 
Inhibition of the elimination of MDZ in RLM by anti-rat CYP1A2, 2C11, 3A2 and 
anti-human CYP2D6 anti-sera were 3.4%, 14.8%, 61.0%, and 10.8%, respectively. In contrast, 
the percentage inhibition of anti-rat CYP3A2 anti-serum on the elimination of MDZ with 
recombinant rat CYP3A2 was 91.3% (Figure 2-1). 
 
 
Figure 2-1  Inhibitory effects of anti-CYP sera on MDZ metabolism in RLM and in 
rrCYP3A2 
Values represent the mean of three experiments. Elimination constants of the control using RLM 
and rrCYP3A2 were 0.192 and 0.140 min
-1
, respectively. 
 
2.3.2  Effects of test inhibitors on MDZ metabolism in RLM 
Since 4- and 1’-hydroxymidazolams are known to be major metabolites of MDZ mediated 
by CYP3A [60], both metabolites were measured. In RLM, 4- and 1’-hydroxymidazolams were 
produced at a ratio of about 2:1 (data not shown). The relationship between inhibitor 
concentration and inhibition percentage on 4-hydroxylation of MDZ in RLM is shown in Figure 
2-2 and the IC50 values for 4- and 1’-hydroxylation are listed in Table 2-1. Diltiazem, mibefradil, 
and verapamil showed marked TDI. In addition, reported values for KI,app and kinact in humans 
are shown in the Table. With the except of clarithromycin and erythromycin, the IC50(-) values 
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for MDZ metabolism in RLM in this study were comparable with those previously reported 
KI,app values in human liver microsomes [15, 42, 62, 63, 64]. The rank order of the value of the 
IC50(-)/IC50(+) ratio in RLM was approximately consistent with that of kinact in human liver 
microsomes. 
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Figure 2-2  Inhibition profiles for MDZ 4-hydroxylation at various concentrations of 
inhibitors in RLM 
Values represent the average of two experiments. Inhibition percentages for coincubation (open 
triangles) and preincubation (closed squares) are shown. 
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Table 2-1  Inhibition (IC50) values of MDZ 4-hydroxylation and 1’-hydroxylation in RLM 
and retrospective data in human liver 
 
Values are the average of two experiments. Potentiation of inhibition by preincubation, namely 
the degree of TDI, is represented by the ratio of IC50(-)/IC50(+). 
 
2.3.3  DDI with mibefradil on MDZ pharmacokinetics in rats 
Plasma concentration-time profiles and pharmacokinetic parameters of MDZ after oral 
administration of 10 mg/kg MDZ with or without mibefradil to rats are shown in Figure 2-3 and 
Table 2-2, respectively. Cmax and AUC values for all groups co-administered with mibefradil 
were significantly elevated in comparison with those of the control group. Tmax values for the 
groups were, respectively, 0.53, 0.63, 0.50, and 0.37 hour, with mean residence time (MRT) 
values of 1.33, 1.27, 1.47, and 3.64 hour. 
Plasma concentration-time profiles of mibefradil after oral administration of MDZ in rats 
are shown in Figure 2-4. The plasma concentration of mibefradil in the 6 mg/kg mibefradil 
pretreatment group was under the lower limit of quantification (1 ng/mL). Plasma concentration 
of mibefradil after 30 min of MDZ administration (approximate Tmax of MDZ) in the 12 mg/kg 
mibefradil pretreatment group was nearly equivalent to that of the simultaneous administration 
group (9.32 and 6.93 ng/mL, respectively). 
 
 
  
IC50(-) IC50(-)/IC50(+) IC50(-) IC50(-)/IC50(+) K I,app k inact
(μmol/L) ratio (μmol/L) ratio (μmol/L) (min-1)
Clarithromycin 167 1.18 145 1.14 41.4
  15
0.0423
  15
Diltiazem 7.30 4.10 9.12 3.66 3.3
  42
0.07
  42
Erythromycin 199 1.05 269 1.07 12.6
  15
0.024
  15
Ethynylestradiol 5.15 1.81 5.79 1.51 18
  64
0.04
  64
Mibefradil 0.476 5.53 0.731 7.17 2.3
  63
0.4
  63
Mifepristone 1.05 1.08 2.91 2.55 4.7
  62
0.089
  62
Verapamil 7.52 2.86 7.86 2.77 2.9
  42
0.15
  42
Midazolam 4-hydroxylation Midazolam 1'-hydroxylation
Rat Human
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Figure 2-3  Plasma concentrations of MDZ after oral administration of 10 mg/kg MDZ 
with and without treatment of mibefradil to rats 
Control (open circles), pretreatment of mibefradil at 6 mg/kg (closed squares) and at 12 mg/kg 
(closed triangles) at 24 hour before MDZ administration, and simultaneous administration with 
mibefradil at 6 mg/kg (closed circles) groups are shown. Values are the mean ± standard 
deviation of five or six rats. 
 
Table 2-2  Pharmacokinetic parameters after oral administration of MDZ simultaneously 
and at 24 hour after mibefradil treatment in rats 
 
Values are the geometric mean (95% confidence intervals) from five or six rats. *p < 0.05, **p<  
0.01, ***p < 0.001, significantly different from the control (Dunnett’s multiple comparison 
test). 
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Pretreatment (time following) Cmax (ng/mL) AUC (ng×hour/mL)
Control (0 h) 51.89 (35.26, 76.38) 71.82 (41.75, 123.56)
6 mg/kg mibefradil (24 h) 123.14
** 
(99.78, 151.98) 162.26
* 
(132.84, 198.21)
12 mg/kg mibefradil (24 h) 265.01
*** 
(173.86, 403.95) 391.43
*** 
(262.44, 583.83)
6 mg/kg mibefradil (0 h) 106.73
* 
(53.54, 212.77) 167.09
** 
(87.41, 319.38)
Oral administration of MDZ at 10 mg/kg
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Figure 2-4  Plasma concentrations of mibefradil after oral administration in combination 
with MDZ to rats 
Results shown are for the groups of 12 mg/kg mibefradil pretreatment at 24 hour before MDZ 
administration (closed triangles) and simultaneous administration of MDZ and 6 mg/kg 
mibefradil (closed circles). Values are the mean ± standard deviation of five or six rats. The 
plasma concentrations of mibefradil for the 6 mg/kg mibefradil pretreatment group with MDZ 
administration after 24 hour (closed squares) was under the limit of quantification (1 ng/mL). 
 
2.4  Discussion 
Evaluation of MBI in animals in vivo in combination with in vitro inhibition assays using 
human enzymes can lead to more accurate predictions of clinical DDI, and clarification of the 
biological impact of DDI in animals in vivo could result in more efficient drug development. 
Although the mechanism-based inhibitors require attention due to unanticipated adverse effects 
[3, 4], there have been no reports in animals showing that the AUC of the probe is elevated due 
to obvious MBI. In this study, it was ascertained that a mechanism-based inhibitor known to 
induce MBI with CYP3A in humans caused MBI in rats. CYP3A4 is the major enzyme in 
oxidative metabolism in humans and is involved in the metabolism of many drugs [12]. Drugs 
that possess inhibitory potential for CYP3A4 appear to indicate a high risk of severe DDI; 
therefore, clarification of the biological consequences of DDI is important. 
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In the investigation of DDI in animals in vivo, it is important to use a probe which is 
metabolized specifically by CYP3A. Since MDZ is metabolized predominantly by CYP3A4 in 
human liver [60, 61] and available as both an in vitro and an in vivo probe, MDZ is generally 
recommended for DDI studies for CYP3A4 [7]. In the current study, we investigated the 
contribution of CYP3A to the metabolism of MDZ in male rat liver, which resulted in a 61% 
inhibition rate of anti-rat CYP3A2 anti-serum in the elimination of MDZ (Figure 2-1). A similar 
study previously reported an 82% inhibition rate of anti-rat CYP3A2 anti-serum in the 
elimination of MDZ in male RLM [65] and CYP3A was thought to predominantly contribute to 
the metabolism of MDZ in male rat liver. However, because the percentage of inhibition of 
anti-rat CYP3A2 anti-serum in RLM was less than in rrCYP3A2 (Figure 2-1), other metabolic 
enzymes appear to contribute to the metabolism of MDZ to some extent. MDZ incubated with 
various recombinant rat CYPs has been reported to produce metabolites largely mediated by 
CYP3A2 and 3A1, but other forms of the CYP2C subfamily produced a smaller amount of 
metabolites [66, 67]. On the basis of these data, even though there is the possibility of slight 
involvement of other enzymes, the main enzyme involved in the metabolism of MDZ is also 
suggested to be CYP3A in rats. 
We explored a strong mechanism-based inhibitor available for the in vivo DDI study. To 
evaluate MBI, we measured the IC50 values in two reaction conditions and applied the ratio of 
the respective values as the index of inhibition. In one reaction, MDZ and an inhibitor were 
added to the enzyme solution simultaneously, and in the other, MDZ was added to the enzyme 
solution after preincubation with an inhibitor. Test inhibitors were clarithromycin [15], diltiazem 
[68], erythromycin [15], ethynylestradiol [64], mibefradil [22], mifepristone [62], and verapamil 
[68], all of which have been reported to cause MBI in humans. Using RLM, mibefradil showed 
the lowest IC50 and the most extensive TDI of the seven inhibitors (Table 2-1), so we selected 
this compound as the indicator for estimation of inhibition in vivo. In fact, mibefradil has been 
withdrawn from the market due to its substantial potential for DDI [69]. The inhibitory effects 
of the test inhibitors in RLM compared with those in human liver microsomes and had IC50(-) 
values against RLM to be nearly equivalent to reported KI,app values against human liver 
microsomes (Table 2-1). In addition, the rank order of magnitude of the IC50(-)/IC50(+) ratio in 
RLM was consistent with that of kinact in human liver microsomes (Table 2-1). These results 
suggested that inhibitors which induce MBI in humans caused MBI in rats, and consequently 
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the inhibition potential of inhibitors could be predicted from in vitro inhibition studies using 
RLM. However, clarithromycin and erythromycin did not induce TDI in this rat liver 
microsomal model system, even though they have been reported to induce MBI in humans. 
Furthermore, the IC50(-) values of these macrolides against RLM were much higher than the 
KI,app values against human liver microsomes. This weak potential for MBI in rats and enzyme 
induction potential is apparently a disparity between humans and rats for the DDI of 
erythromycin. For some inhibitors, there could be species differences in the degree of MBI and, 
concerning DDI, this could impact on the prediction of clinical DDI. To date, research 
concerning species difference in MBI between humans and other species is limited, although 
there have been many reports on the MBI with human CYP3A4. Thus, future research on 
species difference in DDI is required. However, before embarking on in vivo DDI studies in 
animals, assessment of in vitro inhibition studies would be beneficial. 
Using MDZ and mibefradil as the probe and inhibitor of CYP3A, respectively, we 
observed MBI when MDZ was administered in combination with mibefradil to rats in vivo. 
Comparing the groups pretreated with 6 or 12 mg/kg mibefradil and the simultaneous 
administration group, the AUC of MDZ was significantly elevated in comparison with the 
control group (Table 2-2), and DDI was observed. A simultaneous administration group was 
included in the present study in order to observe differences in DDI from competitive inhibition. 
The extent of the elevated AUC for MDZ was about the same for the simultaneous 
administration group and the mibefradil pretreatment group at 6 mg/kg but considerably higher 
for the mibefradil pretreatment group at 12 mg/kg (Table 2-2). Thus, the plasma concentration 
of mibefradil (Figure 2-4) indicates that the DDI in the mibefradil pretreatment group was 
considerably more intense than in the simultaneous administration group. Although DDI was 
observed in the 6 mg/kg mibefradil pretreatment group, the plasma concentration of mibefradil 
was under the quantification limit. This phenomenon can be explained by MBI in which DDI 
was observed despite low level blood concentration of the inhibitor. Additionally, the plasma 
concentration of mibefradil was 8 ng/mL for the 12 mg/kg mibefradil pretreatment group after 
administration of MDZ (Figure 2-4). Assuming that the IC50(-) value in the in vitro inhibition 
study equals Ki, Iu/Ki for mibefradil at 24 hour after administration at 12 mg/kg was calculated 
to be around 0.001 using the reported value for serum protein binding (96.5%) [70], where Iu 
represents unbound concentration of inhibitor in the systemic circulation. This value indicates 
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that competitive inhibition would not occur even in the 12 mg/kg mibefradil pretreatment group. 
In addition, after oral administration of mibefradil to rats, the plasma concentrations of the 
metabolites of mibefradil were significantly lower than the parent drug [70]. Therefore, 
mibefradil, the parent drug, and not its metabolites mainly contributed to the DDI in the 
pretreatment group, suggesting that the DDI observed in the mibefradil pretreatment group was 
due to MBI. Concerning the simultaneous administration group and using the highest reported 
absorption constant (ka) in rats [71], the maximum unbound concentration of mibefradil input to 
the liver (Iin,u) was calculated to be comparable with Ki. This result shows that the competitive 
inhibition of mibefradil might greatly contribute to the DDI of this group. 
We established a simple method for rapidly predicting and categorizing the DDI risk of 
mechanism-based inhibitors of CYP3A4 using simple in vitro experiments and calculations 
utilized in the early discovery stage. This method is effective for screening compounds in the 
drug discovery stage, but there is the possibility that prediction from in vitro data might lead to 
incorrect prediction attributed to the use of uncertain and biased parameters (i.e. the turnover 
rate of enzyme and inhibitor concentration where the inhibitor is uptaken by a transporter or 
highly binds to serum protein) [72]. The present study demonstrates that a mechanism-based 
inhibitor reported to induce MBI in humans caused MBI in rats in vivo as well as in vitro. In 
vivo animal models for the prediction of DDI caused by competitive inhibition have been 
reported [59, 73], but the AUC of a probe is elevated by MBI in animals in vivo has not been 
reported. Recently, to evaluate MBI, a method using an ex vivo isolated perfused rat liver model 
was reported [74]. Compared with this latter method, our method has advantages in that it is a 
convenient in vivo model that can detect responses at the whole-body level. In addition, our 
method is applicable to conditions requiring multiple doses of an inhibitor in which clinical DDI 
caused by MBI is generally observed. More accurate prediction is needed for the selection or 
evaluation of drug candidates in the late stage. Especially, in the case of candidate drugs having 
some degree of MBI potential, implementation of assessment using this in vivo method could 
improve confidence in prediction and consequently lead to more effective decision-making. 
    In conclusion, we have demonstrated MBI of CYP3A in rats in vivo using MDZ as the 
probe. Although a small number of inhibitors showed a degree of interspecies difference 
between humans and rats for DDI in the in vitro inhibition study with liver microsomes, the 
inhibitors which did exhibit MBI in the in vitro study also gave rise to MBI in vivo. The results 
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suggested that evaluation of MBI would be possible in animals in vivo. In combination with in 
vitro DDI evaluation using human enzymes, this method is expected to accurately predict 
clinical DDI and hence be an effective tool for drug development. 
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3. Quantitative prediction of mechanism-based inhibition caused by 
mibefradil in rats 
 
3.1  Introduction 
    Irreversible inhibitors of drug metabolizing enzymes, as represented by mechanism-based 
inhibitors, may cause unanticipated adverse effects on the basis of DDIs. These inhibitors affect 
the blood concentration of a co-administered drug for a long time because they continue to 
inhibit the enzyme until the inactivated enzyme is replaced by a newly synthesized one [3, 4]. 
Guidance from MHLW as well as draft guidance from FDA and EMEA all stipulate the need to 
evaluate MBI [6, 7, 8]. 
    IVIVE methods to predict clinical DDIs from in vitro inhibition data are therefore 
important for drug development. Although Kato et al. recently reported that the prediction 
method for competitive inhibitors using an in vivo inhibition constant (Ki) and a PBPK model 
was more accurate than the conventional method [14], there were inhibitors causing DDIs that 
could not be predicted successfully in the manner of competitive inhibitors, and one of the 
possible reasons is that they were mechanism-based inhibitors. For mechanism-based inhibitors, 
there have also been reports on methods to predict clinical DDIs based on in vitro CYP 
inhibition data, although it is more challenging than predicting competitive inhibitors. Although 
a method of visually and easily categorizing the clinical DDI risk caused by MBI using in vitro 
inhibition data from the early stage of drug development was established as described in 
Chapter 1, for candidate drugs it is necessary to estimate the inactivation parameters and 
evaluate a more detailed DDI risk in the clinic. Reported methods to predict the degree of DDIs 
caused by MBI using in vitro inactivation parameters include a relatively simple method using a 
single inhibitor concentration [10, 11] and a more complicated method using a PBPK model [75, 
76]. For a method using a single inhibitor concentration, the unbound maximum plasma 
concentration (Cmax,u) is often used as the inhibitor concentration to avoid a false negative 
prediction. However, there is a possibility that use of Cmax,u could lead to overestimation of 
DDIs, whereas a method using a PBPK model could predict DDIs more precisely by using the 
change in inhibitor and substrate concentrations over time. In addition, a method using a single 
inhibitor concentration would be unsuited to the case of administering an inhibitor repeatedly, 
which could be overcome by using a PBPK model. 
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  Ethical considerations make it difficult to investigate MBI in humans, so a method of 
verifying it in animals would be valuable. Only a few reports investigating MBI in animals 
including our research as described in Chapter 2 have been published [77]. Demonstrating 
IVIVE in animals seems to increase confidence in predictions of clinical DDIs from in vitro data 
with human tissues. As reported in Chapter 2, after pretreatment with mibefradil, a 
mechanism-based inhibitor of CYP3A, at 6 and 12 mg/kg 24 hour before the oral administration 
of MDZ, a probe substrate, in rats, the Cmax and the AUC of MDZ were significantly elevated in 
comparison with the control. Therefore, we aimed to quantitatively predict the DDI observed in 
rats using a PBPK model from in vitro inactivation parameters in this study. Although it was 
suggested that MDZ was mainly metabolized by CYP3A in rats in Chapter 2, not only CYP3A 
but also CYP2C isozymes were reported to produce metabolites of MDZ in rats [67]. Therefore, 
there is a possibility that CYP2C isozymes are also inactivated by mibefradil. How much 
metabolizing enzymes are involved in eliminating a probe and the potential of an inhibitor to 
inactivate each enzyme are very important factors in the analysis of DDIs. For more precise 
predictions, those parameters of the probe, MDZ, and the inhibitor, mibefradil, were evaluated 
in this study. 
    To establish and verify a predictive model of DDIs caused by MBI, first, ratios of how 
much CYP isozymes contributing to MDZ metabolism were evaluated using recombinant 
microsomes. Then, inactivation parameters of mibefradil were evaluated in recombinant CYPs 
in which MDZ had been metabolized. Finally, a predictive model was constructed by inserting 
the in vitro parameters into the PBPK model representing the plasma concentrations-time 
profiles of mibefradil and MDZ in rats, and it was verified that the model could predict the 
DDIs observed in rats. 
 
3.2  Materials and methods 
3.2.1  Chemicals and reagents 
    MDZ was purchased from Wako Pure Chemical Industries, Ltd (Osaka, Japan). 
4-Hydroxymidazolam, 1’-hydroxymidazolam, and bufuralol hydrochloride were purchased 
from Ultrafine Chemicals Ltd (Manchester, UK). Mibefradil dihydrochloride was obtained from 
Tocris Bioscience (Bristol, UK) and Sigma Chemical Co. (St. Louis, MO, USA) for in vitro 
studies and in vivo studies, respectively. NADPH was obtained from Oriental Yeast Co., Ltd 
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(Tokyo, Japan). Other reagents and solvents used were of the highest or high performance liquid 
chromatography grade. 
 
3.2.2  Biological materials 
    Microsomes prepared from baculovirus-infected insect cells expressing individual rat 
CYP3A2 (rrCYP3A2), CYP2C11 (rrCYP2C11), and CYP2C13 (rrCYP2C13) besides 
cytochrome b5 and cytochrome P450 reductase, and control microsomes were obtained from 
Becton, Dickinson and Company (Franklin Lakes, NJ, USA). Pooled male RLM were 
purchased from Xenotech LLC (Lenexa, KS, USA). 
 
3.2.3  Animals 
Male Sprague-Dawley rats at 8 weeks of age (weighing 271–301 g) were purchased from 
Japan SLC, Inc. (Hamamatsu, Japan). The animals were maintained on a 12 h/12 h, light/dark 
cycle with free access to CE-2 diet (CLEA Japan Inc., Tokyo, Japan) and water. The protocols 
for the animal experiments were approved by our institutional committee for animal care and 
use. 
 
3.2.4  Metabolism of MDZ in recombinant enzymes 
    Metabolic rates of MDZ were evaluated in rrCYP3A2, rrCYP2C11, and rrCYP2C13. The 
enzymes were diluted by 0.1 mol/L potassium phosphate buffer (pH 7.4) at 20 pmol/mL of final 
concentration. Protein concentrations of incubation mixtures were adjusted at 0.2 mg/mL by 
addition of control microsomes. After addition of NADPH to the enzyme solutions at 1 mmol/L 
of final concentration and preincubation at 37°C for 5 min, the reaction was started by adding 
MDZ at 200 nmol/L of final concentration (total volume of the reaction mixture: 900 L). The 
MDZ concentration in reaction mixtures (200 nmol/L) was thought to be considerably lower 
than the Km values of CYP3A2 and CYP2C11 on MDZ metabolism [67, 78]. At 0, 4, 8, and 15 
min, the reaction was stopped by adding 150 L of the reaction mixture to 75 L of acetonitrile 
containing 200 nmol/L bufuralol as the IS. Experiments were conducted in duplicate. 
 
3.2.5  Inactivation of MDZ metabolism by mibefradil 
    After 5-min incubation at 37°C of a reaction mixture (45 L) consisting of 1.11 mmol/L 
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NADPH and 22.2 pmol/mL rrCYP3A2 or 55.6 pmol/mL rrCYP2C11 or 0.222 mg of protein/mL 
RLM in 0.1 mol/L potassium phosphate buffer (pH 7.4), 5 L of mibefradil solution at various 
concentrations in water (rrCYP3A2: 0.625, 1.25, 2.5, 5, 10, and 30 mol/L; rrCYP2C11: 3, 10, 
25, 50, 100, 300, and 900 mol/L; RLM: 1.25, 2.5, 5, 10, and 30 mol/L) was added. In the 
case of rrCYP3A2 and RLM, after a 0-, 1-, 2-, or 5-min preincubation with mibefradil, 10 L of 
reaction mixture was diluted with 188 L of 0.1 mol/L potassium phosphate buffer warmed at 
37°C containing 1 mmol/L NADPH, and the reaction was started by adding 2 L of 20 mmol/L 
MDZ to the mixture immediately. In the case of rrCYP2C11, after a 0-, 2-, 5-, or 10-min 
preincubation with mibefradil, 20 L of reaction mixture was diluted with 178 L of 0.1 mol/L 
potassium phosphate buffer warmed at 37°C containing 1 mmol/L NADPH, and the reaction 
was started by adding 2 L of 20 mmol/L MDZ to the mixture immediately. After 3 min, the 
reaction was stopped by adding 100 L of acetonitrile containing 200 nmol/L bufuralol as the IS. 
Experiments were conducted in duplicate. 
 
3.2.6  In vivo study 
Mibefradil dihydrochloride was dissolved in water at 6 mg/mL or 12 mg/mL as the 
mibefradil concentration. Mibefradil was administered orally at 1 mL/kg to rats under a fed 
condition (n=4). Blood samples were collected from the jugular vein at 0.17, 0.5, 1, 2, 4, 6, 8, 
and 24 hour after administration of mibefradil and immediately centrifuged to obtain plasma 
samples. The plasma samples were kept at approximately -80°C until analysis. 
 
3.2.7  Analysis of MDZ metabolites and mibefradil 
    The concentrations of 1’-hydroxymidazolam, 4-hydroxymidazolam, and mibefradil were 
measured by high-performance liquid chromatography-electrospray tandem mass spectrometry. 
For the in vitro studies, the samples with acetonitrile containing the IS added were 
centrifuged, and 10 L of supernatants were injected into a Quattro IItandem mass 
spectrometer (Micromass Ltd, Manchester, UK) equipped with a MAGIC2002 liquid 
chromatograph (Michrom BioResources, Inc., Auburn, CA, USA) and a HTC PAL autoinjector 
(CTC Analytics AG, Zwingen, Switzerland). The chromatography was performed on a 
Symmetry C18 column (150 × 2.1 mm i.d.; Waters Corp., Milford, MA, USA) with 0.1% 
formic acid-methanol (59:41) as the mobile phase at a flow rate of 200 L/min. The 
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electrospray ionization was operated in the positive ion mode, and quantification was obtained 
using a selected reaction-monitoring method (1’-hydroxymidazolam: m/z 342 > 203, 
4-hydroxymidazolam: m/z 342 > 297, IS (bufuralol): m/z 262 > 188). 
Plasma samples with added IS were prepared with Oasis MCX Elution plates (Waters 
Corp.). After loading samples and washing stepwise with 2% formic acid and methanol, 
analytes were eluted with 40 L of methanol containing 2% ammonium and then 40 L water 
was added. From this solution, 10-L portions were injected into a Quattro micro tandem mass 
spectrometer (Micromass Ltd) equipped with an Alliance 2795 Separation Module (Waters 
Corp.). The chromatography was performed on a SunFire C18 column (30 × 2.1 mm i.d., Waters 
Corp.) at a flow rate of 200 L/min. The mobile phases were A (0.1% formic acid aqueous, v/v) 
and B (methanol containing 0.1% formic acid, v/v). The following gradient program was used: 
0 to 3.5 min, linear change from mobile phase A/B (95:5, v/v) to A/B (5:95, v/v); 3.5 to 4 min, 
maintenance of A/B (5:95, v/v); and 4.1 to 9 min, maintenance of A/B (95:5, v/v). The 
electrospray ionization was operated in the positive ion mode, and quantification was obtained 
by selected reaction-monitoring (mibefradil: m/z 496 > 202, IS (bufuralol): same as above). 
 
3.2.8  Data analysis 
Contribution ratios of CYP isozymes involved in MDZ metabolism. The contribution ratio was 
estimated by multiplying the metabolic rate of MDZ in each microsomes expressing the 
recombinant CYP by the abundance ratio of each isozyme in rat liver. The metabolic rate of 
MDZ was represented by the sum of the production rates of the two major metabolites, 
1’-hydroxymidazolam and 4-hydroxymidazolam, to which MDZ was reported to be almost 
mainly metabolized in rats [61]. The production rate was estimated by dividing the metabolite 
concentration in a linear phase of the metabolite concentration-incubation time plot by the 
enzyme concentration and incubation time. The abundance ratio of each isozyme was found in 
published data [55, 79, 80]. 
 
Kinetic parameters of enzyme inactivation. For incubations in recombinant enzymes and RLM 
with or without mibefradil, the natural logarithm of the percentage of remaining activity 
involved in the production of 1’-hydroxymidazolam or 4-hydroxymidazolam was plotted 
against the preincubation time. The observed inactivation rate constants (kobs) were determined 
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from the slopes of the initial linear decline in activity [9]. The net value of kobs (k’obs) was 
calculated by subtracting the kobs at zero of the inhibitor concentration from the kobs at each 
concentration of the inhibitor. Silverman reported that two principal constants useful in 
describing MBI, kinact and KI,app, can be obtained experimentally [9]. kinact and KI,app represent the 
inactivation rate constant at infinite concentrations of inactivators and the inhibitor 
concentration when kobs is equal to half of kinact, respectively. Values of kinact and KI,app were 
estimated by plotting k’obs against the inhibitor concentration using the nonlinear regression 
program (WinNonlin ver. 5.2; Pharsight, Moutain View, CA, USA) according to eq. (3-1) as 
determined by Silverman: 
     (3-1) 
where I is the initial concentration of the inhibitor [9]. For eq. (3-1), it was assumed that there is 
negligible change in I in the incubation period. 
 
Quantitative prediction of the in vivo DDIs between MDZ and mibefradil. A predictive model 
was constructed by inserting the in vitro parameters into the PBPK model, based on the 
modification of the method of Ito et al. [15]. The differential equations for MDZ (S) and 
mibefradil (I) can be expressed as follows according to the perfusion model (Figure 3-1). 
For MDZ (eqs. 3-2 to 3-5): 
Vliver×(d Sliver/dt) = Qh×Spv - Qh×Sliver/Kp,S - fb,S×CLint,S×Eact/E0×Sliver/Kp,S (3-2) 
Vpv×(d Spv/dt) = Qh×Ssys + Vabs,S - Qh×Spv     (3-3) 
Vabs,S = ka,S×dose×Fa,S×Fg,S×e
-ka,S×t     (3-4) 
Vsys,S×(d Ssys/dt) = Qh×Sliver/Kp,S - Qh×Ssys     (3-5) 
For mibefradil (eqs. 3-6 to 3-9): 
Vliver×(d Iliver/dt) = Qh×Ipv - Qh×Iliver/Kp,I - fb,I×CLint,I×Iliver/Kp,I  (3-6) 
Vpv×(d Ipv/dt) = Qh×Isys + Vabs,I - Qh×Ipv     (3-7) 
Vabs,I = ka,I×dose×Fa,I×Fg,I×e
-ka,I×t     (3-8) 
Vsys,I×(d Isys/dt) = Qh×Iliver/Kp,I - Qh×Isys     (3-9) 
where Sliver, Spv, and Ssys represent the concentration of MDZ in the liver, portal vein, and central 
compartment, respectively; Iliver, Ipv, and Isys represent the concentration of mibefradil in the liver, 
portal vein, and central compartment, respectively; Vliver and Vpv represent the volume of liver 
k’obs = 
kinact × I
KI,app + I
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and portal vein, respectively; Vsys,S and Vsys,I represent the volume of distribution of MDZ and 
mibefradil in the central compartment, respectively; Qh represents the blood flow rate; Kp,S and 
Kp,I represent the liver/blood concentration ratio of MDZ and mibefradil, respectively; fb,S and 
fb,I represent the unbound fraction of MDZ and mibefradil in blood, respectively; CLint,S and 
CLint,I represent the intrinsic metabolic clearance of MDZ and mibefradil, respectively; Vabs,S and 
Vabs,I represent the absorption velocity of MDZ and mibefradil, respectively; ka,S and ka,I 
represent the first-order absorption rate constant of MDZ and mibefradil, respectively; Fa,S, Fa,I, 
Fg, S, and Fg,I represent the fraction absorbed from the gastrointestinal tract of MDZ and 
mibefradil and the intestinal availability of MDZ and mibefradil, respectively; and Eact and E0 
represent the active and total enzyme in the liver, respectively. It was assumed that mibefradil is 
eliminated only by the liver [81]. It was also assumed that non-metabolic clearance of MDZ 
could be negligible, because excretion into urine of unchanged MDZ administered 
intravenously was reported to be less than 0.01% of the dosing amount in rats [82]. It was also 
assumed that the distribution of MDZ and mibefradil in the liver rapidly reaches equilibrium, 
and the unbound concentrations in the hepatic vein are equal to those in the liver at equilibrium 
(well-stirred model). In addition, gastrointestinal absorption is assumed to be described by a 
first-order rate constant. Plasma concentrations of MDZ described in Chapter 2 and mibefradil 
measured by the procedure described above when they were administered solely (Eact = E0) were 
fitted into the PBPK model described above, and CLint,S,, CLint,I, ka,S, ka,I, Vsys,S, and Vsys,I were 
calculated using SAAM II (version 1.2; Saam Institute, Inc., Seattle, WA, USA).  
The differential equation for Eact can be described as follows (eq. 3-10): 
  d Eact/dt = kdeg×(E0-Eact) - R1/100×(kinact,1×Eact×fb,I×Iliver/Kp,I)/(KI,app,1+fb,I×Iliver/Kp,I) – 
R2/100×(kinact,2×Eact×fb,I×Iliver/Kp,I)/(KI,app,2+fb,I×Iliver/Kp,I)   (3-10) 
where kdeg represents the degradation rate constant (turnover rate constant) of enzyme; R1 and R2 
represent the contribution ratio of CYP3A2 and CYP2C11, respectively; kinact,1 and kinact,2 
represent the kinact of mibefradil against CYP3A2 and CYP2C11, respectively; KI,app,1 and KI,app,2 
represent the KI,app of mibefradil against CYP3A2 and CYP2C11, respectively. In the absence of 
mibefradil, the enzyme content in the liver is at steady state, and the degradation rate (kdeg×E0) 
is equal to the synthesis rate, which was assumed to be unaffected by mibefradil. 
    The physiological parameters of rat and pharmacokinetic parameters of MDZ and 
mibefradil used in the simulation are listed in Table 3-1. With the use of SAAM II and kinetic 
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parameters for enzyme inactivation obtained in in vitro studies, the above differential equations 
were numerically solved to simulate the time courses of the active enzyme content in the liver 
(Eact) and MDZ concentration in blood. As described in Chapter 2, the dosing route and regimen 
for the DDI study of MDZ and mibefradil were scheduled as follows. Twenty-four hours after 
oral administration of mibefradil at 6 or 12 mg/kg, MDZ was administered orally at 10 mg/kg. 
Simulated values of MDZ concentrations, Cmax, and AUC were compared with the observed 
data. 
 
 
 
Figure 3-1  Physiological model of the time profiles of MDZ and mibefradil 
concentrations in rats 
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Table 3-1  Physiological parameters of rat and pharmacokinetic parameters of MDZ and 
mibefradil used in the simulation 
 
 
3.3  Results 
3.3.1  Contribution ratios of CYP isozymes involved in MDZ metabolism 
    Contribution ratios of CYP isozymes estimated using the production rate of MDZ 
metabolites in recombinant CYPs and the abundance ratios in the liver taken from publication 
data are shown in Table 3-2. CYP3A2 exists in rat liver to a lesser extent than CYP2C11 but 
metabolized MDZ much more rapidly, suggesting that CYP3A2 mainly contributes to MDZ 
metabolism and CYP2C11 only slightly contributes. Metabolites produced by CYP2C13 were 
Parameter Value Source Reference
Physiological parameter of rat
Body weight 250 g 83
V h 0.011 L 83
V pv 0.00028 L Assumed
Qh 0.882 L/hour 83
E0 5 nmol/g liver CYP3A4 content in the liver in human 84
k deg 0.03 hour
-1 Rat P450 85
MDZ
Dose 2500 g
Fa×Fg 0.78 86, 87
fb,S 0.049 88
Kp,S 1 Assumed
CLint,S 830 L/hour By fitting
CLint,S,1 740 L/hour Using contribution ratio of CYP3A2
CLint,S,2 90 L/hour Using contribution ratio of CYP2C11
k a,S 5.62 hour
-1 By fitting
V sys,S 0.949 L By fitting
Mibefradil
Dose 1500 g
3000 g
Fa×Fg 1 Assumed
fb,I 0.035 70
Kp,I 1 Assumed
CLint,I 6 mg/kg dosed 75.6 L/hour By fitting
12 mg/kg dosed 49.4 L/hour By fitting
k a,I 6 mg/kg dosed 0.174 hour
-1 By fitting
12 mg/kg dosed 0.165 hour
-1 By fitting
V sys,I 6 mg/kg dosed 3.81 L By fitting
12 mg/kg dosed 3.55 L By fitting
k inact,1 23.1 hour
-1 For 4-hydroxylation of MDZ by rrCYP3A2
k inact,2 33.9 hour
-1 For 1'-hydroxylation of MDZ by rrCYP2C11
K I,app,1 130 g/L For 4-hydroxylation of MDZ by rrCYP3A2
K I,app,2 5630 g/L For 1'-hydroxylation of MDZ by rrCYP2C11
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not observed. 
 
Table 3-2  Contribution ratio of CYP isozymes involved in MDZ metabolism in rats 
 
a
 Abundance ratio of each enzyme in the liver was taken from literature. 
b
 Contribution ratio was calculated using the production rate of the two metabolites and the 
abundance ratio. 
 
3.3.2  Inactivation parameters of mibefradil against rrCYP3A2, rrCYP2C11, and RLM 
    Effects of mibefradil concentration and preincubation time on 4- or 1’-hydroxylation of 
MDZ by rrCYP3A2, rrCYP2C11, and RLM are shown in Figure 3-2. In all enzyme sources, the 
production of metabolites decreased according to mibefradil concentration and preincubation 
time, suggesting that TDI was observed. KI,app and kinact values of mibefradil against each 
enzyme are shown in Table 3-3. The kinact in all enzymes were large values and almost similar, 
whereas the KI,app value in rrCYP2C11 was significantly larger than that in rrCYP3A2 and 
RLM. 
 
 
4-hydroxylation 1'-hydroxylation Sum
CYP3A2 0.620 0.369 0.989 14.6 89.1
CYP2C11 0.00432 0.0392 0.0436 40.6 10.9
CYP2C13 N.C. N.C. N.C. 12.7 N.C.
N.C.: not calculated
Metabolic rate (pmol/min/pmol CYP) Abundance ratio 
a 
(%)
Contribution ratio 
b 
(%)
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Figure 3-2  Effects of mibefradil concentration and preincubation time on MDZ 
hydroxylation by rrCYP3A2 (A), rrCYP2C11 (B), and RLM (C) 
The y-axis represents the formation rate of 4-hydroxymidazolam (A and C) or 
1’-hydroxymidazolam (B). The control activities were 12.2 pmol/min/pmol CYP (A), 2.77 
pmol/min/pmol CYP (B), and 2.12 pmol/min/g protein (C). 
 
Table 3-3  Inactivation parameters of mibefradil on MDZ metabolism in rrCYP3A2, 
rrCYP2C11, and RLM 
 
 
3.3.3  Plasma concentrations of mibefradil in rats 
    Figure 3-3 shows plasma concentration-time profiles of mibefradil after oral administration 
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at 6 or 12 mg/kg in rats and also shows estimated values that were obtained by fitting values 
into the model represented in Figure 3-1. Estimated plasma concentrations 24 hour after 
administration were close to the observed values, whereas estimated values 10 or 30 min after 
administration were lower than the observed values. The ka and Vsys values of mibefradil 
estimated by the fitting were almost similar between 6 and 12 mg/kg (Table 3-1). However, the 
CLint values at 6 and 12 mg/kg were estimated to be 75.6 and 49.4 L/hour, suggesting 
non-linearity. 
 
 
Figure 3-3  Plasma concentrations of mibefradil after oral administration at 6 and 12 
mg/kg in rats 
Closed triangles and squares represent observed values at 6 and 12 mg/kg, respectively. Dashed 
and solid lines represent simulated values at 6 and 12 mg/kg by the fitting calculation, 
respectively. 
 
3.3.4  Prediction of DDIs caused by MBI 
    In the study described in Chapter 2, as a result of oral administration of mibefradil at 6 or 
12 mg/kg 24 hour before oral administration of MDZ in rats, it was shown that plasma 
concentrations of MDZ were elevated compared with the control. The DDI was predicted using 
the model represented in Figure 3-1. The prediction showed that active content of CYP3A2 was 
significantly reduced by administration of mibefradil, although that of CYP2C11 was reduced 
1
10
100
1000
0 6 12 18 24
P
la
sm
a 
co
nc
en
tr
at
io
n
(n
g/
m
L
)
Time after administration (hour)
52 
 
less than or comparable to 20% even at 12 mg/kg mibefradil (Figure 3-4). Active content of the 
total enzymes in the liver was predicted at a time profile similar to that for CYP3A2. 
    Observed and predicted plasma concentrations of MDZ with and without co-administration 
of mibefradil are shown in Figure 3-5, and Cmax and AUC values in those groups are shown in 
Table 3-4. The model predicted that co-administration of mibefradil would elevate MDZ 
concentration, and the predicted increases in MDZ concentrations, Cmax, and AUC resulting 
from the co-administration closely corresponded to the observed values. 
 
 
Figure 3-4  Predicted change in active CYP contents after the administration of 
mibefradil at 6 mg/kg (A) and 12 mg/kg (B) in rats 
Dashed, thin, and heavy lines represent the change in CYP3A2, CYP2C11, and total CYP 
contents, respectively. 
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Figure 3-5  Predicted and observed plasma concentrations of MDZ in rats with or 
without pretreatment with mibefradil 
Open circles, triangles, and squares represent the observed values of the control and 
pretreatment with mibefradil at 6 and 12 mg/kg, respectively. Dashed, thin, and heavy lines 
represent the predicted values of the control and pretreatment with mibefradil at 6 and 12 mg/kg, 
respectively. 
 
Table 3-4  Comparison of observed and predicted Cmax and AUC values of MDZ in rats 
with or without pretreatment with mibefradil 
 
Mibefradil was administered orally 24 hour before MDZ administration. Predicted value was 
evaluated using the model and parameters in Figure 3-1 and Table 3-1. 
 
3.4  Discussion 
    We thought that when a decision on the development of candidate drugs possessing a 
potential for MBI is being made, an evaluation of in vivo MBI in animals coupled with an 
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Observed Simulated Observed Simulated Observed Simulated
Cmax (ng/mL) 51.9 55.4 123 153 265 269
100 100 237 276 511 485
AUC0-3hour (ng×hour/mL) 71.8 80.1 162 227 391 408
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evaluation of in vitro DDIs using human enzymes would increase the levels of confidence for 
that decision. We therefore verified whether an inhibitor that exhibits MBI in humans also gives 
rise to DDIs in rats by ascertaining that pretreatment with mibefradil significantly elevated Cmax 
and AUC values of orally administered MDZ compared with the control in Chapter 2. In this 
study, to further increase confidence levels, we aimed to quantitatively predict the DDIs 
observed in rats from in vitro inactivation data. 
To predict DDIs caused by the inhibition of metabolism, the contribution ratios of enzymes 
involved in the metabolism of a drug involved in an interaction are critical factors to be 
considered. Although it was reported by us and other laboratories that MDZ was mainly 
metabolized by CYP3A in rats [65], CYP2C isozymes were also reported to produce 
metabolites of MDZ [67]. CYP3A4 is the most highly expressed CYP isozyme in human liver 
[53], whereas in rat liver CYP2C11 is highly expressed [55], and CYP2C13 was reported to be 
comparable to CYP3A2 [55]. Thus, first, the contribution ratios of CYP3A2, 2C11, and 2C13 
involved in MDZ metabolism were evaluated using the production rate of metabolites in 
recombinant CYPs and the abundance ratios in rat liver [55, 79, 80]. Because it was reported 
that the major metabolites were 4-hydroxymidazolam and 1’-hydroxymidazolam in rats as well 
as in humans [61], the production rates of these two metabolites were used for the estimation. 
The result showed that the production rate by CYP3A2 was extremely large, but no metabolites 
produced by CYP2C13 were observed (Table 3-2). Compared with the results reported by 
Chovan et al.[67], the rate by CYP3A2 was relatively more rapid in our study. However, the 
result that CYP3A2 and 2C11 preferentially produced 4-hydroxymidazolam and 
1’-hydroxymidazolam, respectively, was identical. Because of the metabolic rate, CYP3A2 was 
suggested to be the major enzyme involved in MDZ metabolism despite its being less abundant 
in the liver. 
Next, the potential of mibefradil to exert MBI on CYP3A2 and CYP2C11 was evaluated. 
Because mibefradil was reported to induce MBI against CYP3A4 and CYP2C8 in humans [89], 
it was considered likely that isozymes other than CYP3A in rats are also inactivated by 
mibefradil. As a result of evaluating the inhibitory activity of mibefradil on MDZ metabolism 
using recombinant microsomes, the effects of mibefradil concentration and preincubation time 
were observed against not only CYP3A2 but also CYP2C11 (Figure 3-2), suggesting that 
mibefradil induced MBI against both isozymes. A comparison of the inactivation parameters of 
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the isozymes showed that kinact values of both isozymes were large, and no obvious difference in 
the values was observed (Table 3-3). On the other hand, the KI,app value of CYP3A2 was 
considerably lower than that of CYP2C11, thereby suggesting that mibefradil caused MBI 
against CYP3A2 more intensely. In addition, the parameters of mibefradil against RLM were 
very similar to those against CYP3A2. This result appears to indicate that MBI by mibefradil 
was mainly dependent on the inactivation of CYP3A2. 
Next, to verify whether prediction of in vivo DDIs from in vitro data is possible, a 
predictive model for MBI was constructed. For the prediction, we used a PBPK model, which 
represents changes in inhibitor and substrate concentrations over time and has the advantage of 
a detailed DDI analysis (Figure 3-1) [15]. To construct the PBPK model, plasma concentrations 
of an inhibitor, mibefradil, administered solely were measured (Figure 3-3). As a result of fitting 
calculations of the observed concentrations into the PBPK model, the CLint value at 12 mg/kg 
was smaller than that at 6 mg/kg, in brief, non-linearity in the elimination phase was observed 
(Table 3-1). The phenomenon that plasma concentrations of mibefradil rose more than the 
dosage ratio had been observed in humans previously [22]. According to a report on the 
metabolic pathway of mibefradil, oxidative metabolites were major [90]. Therefore, this 
non-linear pharmacokinetics seemed to occur as a result of the autoinactivation of metabolism 
of mibefradil by MBI. Because of the non-linearity, pharmacokinetic parameters of mibefradil 
were estimated and used for the prediction separately at each dose. Plasma concentrations of 
mibefradil calculated by the fitting were consistent with the observed values except for the 
initial period after administration. Thus, it was judged that there was no problem with the 
prediction of the DDI when MDZ was administered 24 hour after mibefradil administration. 
Then, we predicted the DDI by inserting the in vitro parameters into the PBPK model 
constructed. It was defined that CYP3A2 and CYP2C11 contribute to MDZ metabolism at the 
contribution ratios shown in Table 3-2, and inactivation of the two isozymes occurs according to 
the inactivation parameters shown in Table 3-3. In the model, mibefradil administered at 6 or 12 
mg/kg was predicted to reduce active CYP content in the liver (Figure 3-4) and increase plasma 
concentrations of MDZ (Figure 3-5), consequently causing MBI. Predicted increases in the 
Cmax and AUC of MDZ with the co-administration of mibefradil closely corresponded to the 
observed values (Table 3-4). In the above prediction, it was assumed that intestinal metabolism 
is not affected by mibefradil administration, because it was reported that Fa,S×Fg,S of MDZ was 
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relatively high (approximately 0.8) in rats [86, 87]. If it was assumed that intestinal metabolism 
was entirely inhibited by mibefradil (Fa,S×Fg,S of MDZ = 1), Cmax and AUC of MDZ 
co-administered with mibefradil were predicted to increase up to approximately 30% (196 
ng/mL and 291 ng×hour/mL at 6 mg/kg mibefradil and 344 ng/mL and 524 ng×hour/mL at 12 
mg/kg mibefradil, respectively) compared with prediction results without inhibition of intestinal 
metabolism. Although in this study the prediction for which intestinal metabolism was not 
inhibited was closer to the observed results, it may be desirable to predict DDIs both with and 
without the intestinal metabolism being inhibited because a methodology for predicting 
inactivation of intestinal enzymes has not been established. However, in this study, it was 
thought that both prediction results would almost correspond to the observed data. In addition, 
in the prediction of MBI, kdeg is a very important factor. Because rigorous values of kdeg of rat 
CYP isozymes have not been clear yet, we assumed that kdeg values of rat CYPs are the same. 
Under such an assumption, the prediction gave results close to the observed data. These results 
demonstrate that construction of a predictive model using the PBPK model in detail would 
enable a precise prediction of DDIs caused by MBI. As shown above, verification that the 
results predicted from in vitro data correspond to the in vivo data in animals will increase 
confidence in results predicted by the same method in humans. 
In this study, because two isozymes, CYP3A2 and CYP2C11, contribute to MDZ 
metabolism, their contribution ratios and inactivation parameters were inserted into the 
predictive model. As far as we know, this is the first study in which inserting inactivation of 
multiple isozymes into the predictive model of DDIs using a PBPK model was tried. Perhaps 
because of the difference in KI,app values, active CYP3A2 content was predicted to be decreased 
considerably by mibefradil, whereas active CYP2C11 content was predicted to decrease slightly 
(Figure 3-4). The change in active content of total enzymes covered by the two enzymes was 
almost similar to that of CYP3A2, suggesting that the DDI between MDZ and mibefradil in rats 
may be mostly accounted for by the contribution of CYP3A2. Although in this study it was 
predicted that the inactivation of one enzyme contributes significantly to the DDI, considering 
the inactivation of multiple isozymes contributing to substrate metabolism would be meaningful 
for a more accurate prediction. Because there are many drugs metabolized by multiple enzymes 
in clinical practice, this approach is expected to contribute to improved prediction accuracy. 
In conclusion, it was suggested that the DDI between MDZ and mibefardil in rats was 
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caused by inactivation of CYP3A2 mainly and CYP2C11 slightly. As a result of predicting the 
DDI using the PBPK model with in vitro inactivation parameters against both enzymes inserted, 
predicted values for the increase in MDZ concentrations closely corresponded to the observed 
values. This result demonstrates that the construction of a predictive model for DDIs using the 
PBPK model in detail would enable us to predict in vivo DDIs accurately. Verification that the 
results predicted from in vitro data correspond to the in vivo data in animals will increase 
confidence in results predicted by the same method in humans. Prediction of DDIs based on the 
contributing isozymes as shown in this study is expected to be applied to the prediction of 
clinical DDIs of drugs metabolized by multiple enzymes. 
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Concluding remarks 
 
Summary of the studies and consideration of the evaluation strategy 
    MBI is recognized as an issue that must be addressed in the development of new drug 
entities because mechanism-based inhibitors have been reported to cause unanticipated adverse 
effects arising from DDIs, and actually some such dangerous drugs have already been 
withdrawn. Mechanism-based inhibitors found to have a high risk of DDIs after they have been 
launched onto the market or at a late stage of the drug development process not only potentially 
injure patients, but can also cause pharmaceutical companies marked losses in time and 
resources. Therefore, strategies that consider the evaluation of MBI throughout the whole drug 
development process are required to prevent finding out MBI-based DDIs only after the drugs 
are in clinical use and to avoid the loss of potentially effective drugs. 
    In this research, I aimed to establish an evaluation strategy for predicting MBI-based DDIs 
for application from the early stage through to the late stage of drug development, to effectively 
produce safe drugs with low MBI potential. To achieve the purpose, I tried to establish 
prediction methods and evaluation models that are useful in the early discovery stage and in the 
late stage. 
  
In Chapter 1, a simple method of assessing the risk of DDI caused by MBI was first 
developed for use in the early discovery stage, based on CYP3A4 inhibition screening data. 
CYP3A4 inhibition was evaluated using a fluorescent substrate in conditions with or without 
preincubation containing an inhibitor. The results produced with five well-known 
mechanism-based inhibitors and one well-known competitive inhibitor suggested the utility of 
the IC50 shift induced by preincubation in identifing mechanism-based inhibitors. A method to 
approximately predict and visually categorize the change in the AUC of a co-administered drug 
caused by MBI was also developed using the IC50 shift data and the unbound mean plasma 
concentration of the inhibitor. The changes in the AUCs of 38 drugs were predicted using this 
method, and all mechanism-based inhibitors that caused changes in the AUC of more than 200%, 
except for ritonavir, were categorized to be high risk by this prediction. Drugs reported not to 
cause DDIs were not predicted to be high risk. This method could provide the simple 
assessment of the risk of DDIs from mechanism-based inhibitors, especially in the early stages 
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of drug development. 
 
    In Chapter 2, an in vivo model of DDIs caused by MBI of CYP3A was established in rats. 
It has never been reported that the AUC of a probe drug is elevated by MBI in animals. 
However, if it is possible to establish an in vivo animal model for evaluating DDI caused by 
MBI, it would make an impact on judgment of drug development. In this study, I examined 
whether the mechanism-based inhibitors reported to induce DDIs in humans also cause MBI in 
rats. Before any in vivo assessment was made, an inhibition study with anti-CYP sera in RLM 
suggested that MDZ is mainly metabolized by CYP3A in rats. In inhibition studies with or 
without preincubation containing well-known CYP3A inhibitors on MDZ metabolism in RLM, 
mibefradil showed the lowest IC50 and the most extensive TDI of the seven inhibitors tested. 
Therefore, MDZ and mibefradil were selected as the probe and inhibitor of CYP3A, 
respectively, in the in vivo study. Following oral pretreatment of mibefradil at 6 or 12 mg/kg 24 
hour before oral administration of MDZ, the Cmax and AUC values for MDZ were significantly 
elevated in comparison with the control. The free plasma concentration of mibefradil was 
substantially lower than the IC50 value observed in the in vitro study, suggesting that the DDI 
was attributable to MBI. In combination with an in vitro DDI evaluation using human enzymes, 
this in vivo method could increase our confidence in predicting DDIs, and consequently 
allowing us to make more effective decisions during drug development. 
 
    In Chapter 3, to further increase our confidence levels of the prediction of DDIs, I verified 
the quantitative prediction of the DDIs observed in rats using a PBPK model from in vitro 
inactivation parameters. To ensure more precise predictions, the contribution ratios of the CYP 
isozymes involved in MDZ metabolism and the inactivation parameters of mibefradil for each 
isozyme were incorporated into the predictive model. Evaluation of the metabolic rate using 
recombinant CYPs suggested that CYP3A2 mainly contributed and CYP2C11 slightly 
contributed to MDZ metabolism in rats. Studies of the inactivation of the two isozymes by 
mibefradil also showed that the kinact values were considerable for both isozymes, whereas KI,app 
for CYP3A2 was a good deal lower than that for CYP2C11. A predictive model was constructed 
by inserting the in vitro parameters into the PBPK model representing the plasma 
concentration-time profiles for mibefradil and MDZ in rats. As a result of prediction of DDIs, 
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the predicted increases in AUC and Cmax of MDZ after pretreatment with mibefradil closely 
corresponded to the observed values. These results demonstrate that the construction of a 
predictive model for DDIs using a PBPK model in detail allows us to predict in vivo DDIs 
accurately. Verification that the results predicted from in vitro data correspond to the in vivo data 
in animals will increase our confidence in results predicted with the same method in humans. 
The prediction of DDIs based on the contributing isozymes, as shown in this study, is expected 
to be applied to the prediction of clinical DDIs of drugs metabolized by multiple enzymes. 
 
    Using these methods and models for the evaluation and prediction of DDIs caused by MBI, 
I have devised an evaluation strategy applicable from the early discovery stage through to the 
late development stage (Figure 0-1). First, in the early discovery stage, we can screen much 
many compounds using the simple categorization method described in Chapter 1. Because this 
categorization method can provide results very rapidly with simple experiments, it is suitable 
for the early stage when an extraordinarily large number of compounds must be evaluated. The 
method also provides a rough guide, with simple prediction, to how much we must reduce the 
MBI potential, consequently allowing the efficient selection of candidate drugs. In the stage 
when candidate drugs are narrowed down, more accurate prediction of DDIs is required to make 
a decision of development. Clinical DDIs are usually predicted with a simple equation that 
calculates the change in the AUC of a co-administered drug using the in vitro inactivation 
parameters and the single inhibitor concentration without time course. However, for accurate 
decisions of drug development, another evaluation that can complement the easy prediction may 
be required, especially in the case of candidate drugs with some degree of MBI potential. In 
such cases, we can verify whether the candidate drugs cause DDIs with the in vivo animal 
model for DDI and IVIVE described in Chapter 2 and 3. After the confirmation that the 
candidate drugs can also inactivate CYP3A in rats in in vitro inactivation assays using rat 
enzymes, we can predict DDIs in rats by establishing a predictive model and evaluate the 
candidate drugs using the in vivo model when administered the candidate drugs at doses decided 
by reference to the effective dose in pharmacological studies. In vivo evaluation can assess the 
responses of the whole body, which involves phenomena that are difficult to anticipate from in 
vitro studies, and it should enhance the understanding of chemists and pharmacologists. It is 
easy to perform experiments in this model and it is applicable in situations where multiple doses 
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of an inhibitor are required, which are typical of clinical MBI-based DDIs. In combination with 
the in vitro DDI evaluation using human enzymes, assessment using this in vivo method could 
increase our confidence in any prediction. Furthermore, we can verify the quantitative 
prediction of in vivo DDIs from rat in vitro inactivation data by constructing a predictive model 
from the PBPK model. If IVIVE is verified successfully, the validity of the prediction method 
for the candidate drug would be confirmed. This will further increase our confidence in the 
results predicted with the same method in humans, allowing more effective decisions to be 
made during drug development. Moreover, the results of in vitro and in vivo DDI studies in 
animals could be exploited to improve the design of clinical DDI studies. In conclusion, the 
strategy I adopted to predict DDIs caused by MBI throughout the different stages of drug 
development can facilitate the more efficient development of new safe medicines with a reduced 
risk of DDIs. 
 
 
 
Figure 0-1  Flow chart of the strategic evaluation of DDIs caused by MBI 
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investigated MBI and methods of predicting the DDIs caused by MBI in the liver. However, the 
small intestine is also an important organ in drug metabolism, but it is very difficult to establish 
a method that predicts MBI in the small intestine. Therefore, no confirmed method has yet been 
reported. I believe that a method of evaluating MBI in the small intestine and a model of 
predicting DDIs containing those caused in the small intestine should be established in the 
future. 
    In this research, I also investigated some DDIs of CYP3A, which is thought to be the most 
important enzyme in MBI research. However, there are examples of mechanism-based 
inhibitors that cause severe DDIs concerning other enzymes. Therefore, I believe that it is 
required to apply the methodology described in this research for other metabolic enzymes. 
    I aim to continue research into DDIs to be able to produce effective and safe medicines for 
patients rapidly. 
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